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Resumo 
 
A dificuldade em desenvolver antibióticos mais eficientes, numa altura 
em que a resistência microbiana tem vindo a aumentar, torna essencial 
o desenvolvimento de terapias alternativas, económicas e eficazes. Os 
anticorpos obtidos a partir da gema de ovo de galinha, imunoglobulina 
Y (IgY), têm-se destacado não só pela sua produção mais simples e em 
maior quantidade em relação aos anticorpos policlonais de mamífero, 
mas também devido às inúmeras vantagens em termos de aplicações. 
No entanto, atualmente não existe uma plataforma de purificação de IgY 
que seja económica, eficaz e passível de aplicação a nível industrial - 
uma lacuna que este trabalho se propõe a resolver. Assim, neste 
trabalho, estudou-se a possibilidade da utilização de sistemas aquosos 
bifásicos (SAB) compostos por PEG 1000 e tampão fosfato 
(K2HPO4/KH2PO4) ou K2HPO4, seguidos de um passo de ultrafiltração, 
ou acoplados à tecnologia de cromatografia de partição de força 
centrífuga (CPC), para a purificação de IgY. Foram avaliados os efeitos 
de pH (5,5; 6,0; 6,5; 7,5; e 8,0) e composição de PEG e sal na extração 
de IgY, bem como as condições utilizadas na CPC (fluxo da fase móvel, 
rotação e modo de operação). Foi estudada a estabilidade do anticorpo 
em soluções aquosas dos componentes utilizados nos SAB utilizando 
dicroísmo circular, assim como a atividade/estabilidade do anticorpo 
após o processo de purificação por ELISA, salientando assim o efeito 
do PEG 1000 na estrutura secundária e na atividade do IgY. O ATPS 
constituído por 18 % PEG 1000 + 13 % tampão fosfato a pH 6,0 conduz 
aos melhores resultados em termos de purificação, obtendo-se num 
único passo de extração uma pureza de IgY de 39 %. Após a aplicação 
de CPR, obteve-se IgY com um grau de pureza de 51 %, e com 
ultrafiltração, IgY com um grau de pureza de 47 %. Face aos resultados 
obtidos, destaca-se a CPR como a técnica mais adequada dado que 
permite obter IgY com um maior grau de pureza e ser passível de 
aplicação à escala industrial. 
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Abstract The difficulty in developing more effective antibiotics, at a time where 
the microorganism’s resistance to them has been increasing, turns 
essential the development of cheaper and effective alternative 
therapeutics. Antibodies obtained from the chicken’s egg yolk, 
immunoglobulin Y (IgY), have stood out because of their production 
simplicity and production in higher quantity when compared to mammal 
polyclonal antibodies, and also because of their advantages in terms of 
applicability. Nonetheless, there is still no low-cost, effective and 
scalable platform for the IgY purification - a vacuity that this work aims 
to solve. Therefore, in this work, the possibility of using aqueous biphasic 
systems (ABS) composed of PEG 1000 and phosphate buffer 
(K2HPO4/KH2PO4) or K2HPO4, followed by an ultrafiltration step, or 
coupled with centrifugal partition chromatography (CPC), was studied. 
The effect of pH (5.5; 6.0; 6.5; 7.5 and 8.0) and the PEG + phosphate 
buffer composition in the extraction of IgY was investigated, as well as 
the conditions to be used in CPC (mobile phase flow rate, rotation, and 
the operation mode). The stability of the antibody in aqueous solutions 
of the components used in the ABS formation was studied using circular 
dichroism, as well as the activity/stability of the antibody after the 
purification process, by ELISA, primarily outlining the effect of PEG 
1000 in the secondary structure and activity of IgY. The ABS composed 
of 18 wt % PEG 1000 + 13 wt % phosphate buffer at pH 6.0 yielded the 
best results in terms of purification, achieving a 39 % IgY purity in a 
single extraction process. After the application of CPC, an IgY purity of 
51 % was obtained, and with the ultrafiltration technique a purity of 47 
% was obtained. According to these results, CPC appears as the most 
adequate purification technique due to the higher purity of IgY obtained 
and possibility of being applied at an industrial level. 
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1.1. Context and Objectives 
While the use of antibiotics has been increasing, the antibacterial pipeline is scarce 1,2, giving 
rise to significant antimicrobial-resistant infections as a result of the microbe’s potential to mutate 
and adapt to treatment 3,4. Thus, there is an enormous need for alternative therapies, which include 
other pharmaceuticals, such as biopharmaceuticals, in addition to antibiotics. The classic definition 
of biopharmaceuticals refers to compounds of biological nature with biological/therapeutic activity, 
manufactured using biological sources and processes 5. These compounds have been seen as 
promising alternatives to conventional pharmaceuticals, from the historical example of insulin for the 
treatment of diabetes 6, the use of coagulation factors, such as Factor VIII and IX, for the treatment 
of both A and B types of hemophilia 7–9, modified growth hormones against acromegaly 10, and  the 
use of retroviruses against serious infectious diseases, like the Human Immunodeficiency Virus (HIV) 
11. In 2015, nearly 250 biopharmaceuticals have been approved for sale in the United States of 
America (USA) and in the European Union (EU), while the sales of therapeutic proteins cumulatively 
reached 140 billion US$ by 2013, with antibodies representing a large fraction of the overall 
biopharmaceutical approvals (27 %, 75.7 billion US$) 12. 
Polyclonal antibodies, such as immunoglobulin G (IgG), can be obtained from mammal’s 
blood, such as horses, sheep, and rabbits 13,14, while monoclonal antibodies are typically obtained by 
the use of cell cultures 15. Nevertheless, viable alternatives from hen egg yolk have been suggested, 
namely the avian antibody immunoglobulin Y (IgY), as a functionally equivalent antibody of IgG 16. 
The collection of IgY minimizes the ethical concerns with the standard practices of antibody 
production from mammal’s blood 17. Concerning the applicability of IgY, there are also advantages 
to be found by exploring the evolutionary distance between mammals and birds, since this fact allows 
the production of antibodies against highly conserved mammalian proteins, providing a more efficient 
immune response, and bypassing the activation of interference factors like the complement system or 
by human anti-mouse antibodies, unlike mammalian antibodies 18. Despite these advantages, the 
common use of IgY is still restricted by difficulties in its isolation and purification from the egg yolk 
complex matrix, requiring improvements in the current purification techniques and/or development 
of new ones 19. 
The downstream processing of biopharmaceuticals is a critical part of their production, 
accounting, for instance, with 50 % to 80 % of the total manufacturing costs in the case of therapeutic 
antibodies 20. The need of optimizing this part of the process is a crucial demand to allow a viable 
upscale production of antibodies and to decrease their current cost. The antibodies separation and 
purification are usually performed by solid-liquid chromatography 21; however, Aqueous Biphasic 
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Systems (ABS) have been studied as a possible alternative 22. ABS are a liquid-liquid extraction 
technique, being a primary stage unit used in the downstream processing of many biological products, 
like cells, viruses, proteins, and antibodies 23. These systems are prepared by the mixing of two phase-
forming components in water, that above-given concentrations undergo phase separation while 
providing a suitable water-rich environment for maintaining the biological activity of many 
biomolecules 24,25. Since the introduction of ABS by Albertsson 26, multistage extractions using ABS 
have been an ambition aiming at increasing the purification factors of target products. In 1964, the 
introduction of centrifugal partition chromatography (CPC) 27 turned this ambition into a reality, and, 
in recent years, there have been some examples of successful use of CPC for the separation of 
biochemical products 28–30. CPC is a chromatographic separation technique, based on the principles 
of liquid-liquid extraction, that features a series of chambers mounted on a disk, connected from the 
top of one to the bottom of another, that rotates on an axis, and creating a centrifugal force field 27.  
The stationary phase is loaded while the other phase is pumped through, creating a waterfall-like 
mechanism mixing the mobile phase and the stationary phase in each chamber 27. This technique has 
several advantages, detailed in further chapters, but the easy scale-up and industrial adaptation of the 
process, as well as other economic and environmental factors 27,31, make it especially relevant to the 
goal of this work. 
The main objective of this work conveys on the study of the fast centrifugal partition 
chromatography (FCPC) technique with ABS for the purification of IgY from egg yolk, envisaging 
the purification technique scale-up and a decrease of these biopharmaceuticals costs. The target 
antibody selected is IgY, not only due to the relative advantages in terms of applicability, but also 
because of the efficiency of its production 32. PEG/salt-based ABS have been chosen since these 
systems have phase-forming components of relatively low cost, provide a stable and fast phase 
separation, display an adequate density difference between the two phases, and are well documented 
and characterized in terms of phase diagrams 33. The use of the FCPC technology coupled with the 
bio-suitable environment provided by ABS may provide an important step into obtaining cheaper and 
widely available biopharmaceuticals, as envisioned and demonstrated with this work. 
 
1.2. Production and applications of antibodies 
Antibodies, found in plasma and extracellular fluids, are involved in the defense of an 
organism by connecting to foreign and adverse substances, further activating a cascade of reactions 
that ultimately lead to the neutralization and destruction of these. The compounds that antibodies 
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connect to are referred to as antigens and are usually proteins, glycoproteins or polysaccharides 34, 
but also encompasse a wide range of chemicals, like metals, toxins, among others 35. 
The immune system branches out into two types of responses, innate and adaptive; the first 
occurs fast but is non-specific, while the second, albeit slower, is specific and can lead to long-term 
protection 36. The innate response starts in the immediate moment of infection and, on a first stage, 
lasts for up to four hours. It is based on the deployment of preformed solutions in the blood, 
extracellular fluids, and epithelial secretion, to either kill the pathogen outright or weaken its effect. 
These solutions include several antimicrobial substances: enzymes, like lysozyme, to digest the 
bacterial walls; peptides, like defensins, that lyse the bacterial cell membranes directly; and the 
plasma proteins of the complement system responsible for the targeting of pathogens for lysis and 
phagocytosis 37. After the first four hours, and until the activation of the adaptive response, the cells 
responsible for innate immunity begin recognizing molecules typical to microbes and foreign to the 
host – pathogen-associated molecular patterns – and start to activate effector cells and inducing 
inflammation, in an attempt to halt the pathogens progress 37,38. 
There are two general types of antibodies, monoclonal antibodies (mAbs) and polyclonal 
antibodies (pAbs),  and the traditional production of both begin in the same manner - by inoculation 
with an antigen or a mixture of antigens and, if the antigens used are poorly immunogenic, with an 
adjuvant to increase the immune response 42. The choice of the animal used plays a significant part 
in the production process, as factors like the amount of antibody needed and its intended use, the 
easiness of handling the animals, and the phylogenic distance between the antigen and the animal 
species, have to be taken into account 42. After this first step, and after the time required for the 
immune response to occurs, the process differs between the two types of antibodies. Antigen 
inoculation for mAbs production trigger the activation of specific B-cells that then have to be 
harvested, usually from the animal’s spleen, and fused with a type of cancerous immune cell that 
allows for the indefinite proliferation of the fused B-cell, a myeloma 43. In the case of pAbs, the usual 
process relies on their extraction and purification from the serum of immunized mammals 44. The 
production of antibodies from cell cultures is also an important alternative methodology since these 
cultures provide higher amounts of consistent products from a single cell clone 45. This technique is 
based on the introduction of an expression vector plasmid, designed to contain the desired antibody’s 
Lc and Hc genes and a special selector gene, to a cell culture that contains a selector agent 46. The 
selector gene in the added plasmid, along with the selector agent in the culture, ensure that only the 
cells transformed by the plasmid survive after some time 46. The surviving cells are then collected 
and allowed to proliferate in a second cultivation vessel, after which individual clones are tested for 
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production efficacy of the target antibody, with the most efficient clones being chosen for scale up 
and long-term expression 45.  
The applications of pAbs and mAbs are diverse, with both types of antibodies presenting their 
advantages and disadvantages, not only in terms of production but also in applicability. Concerning 
the production of antibodies, there is a notable difference between these two classes. For instance, 
pAbs can be faster generated and at a lower expense, usually being ready some months after the first 
immunization 47. In contrast, the process of generating hybridomas can add a considerable time 
expense to the production of mAbs, requiring up to a year in some cases and presenting significant 
costs 47. The process for achieving effective antibody production with cell cultures is also significantly 
laborious, due to the requirement of analyzing and selecting efficient clones for production 15. In spite 
of time-consuming and expensive production requirements, mAbs have considerable advantages in 
terms of homogeneity and consistency, since they are highly specific and thus useful in many 
therapeutic scenarios 48. mAbs are also better suited for evaluating small changes in molecular 
conformation 49, protein-protein interactions 50, and phosphorylation state 51. There are, however, 
situations where the advantages of mAbs are reduced, particularly regarding their specificity and 
homogeneity that can prevent them from adequately recognizing an epitope when small changes 
occur to it, be it by genetic polymorphism, glycosylation or even by small changes in the structure 
brought about by denaturation. Since they recognize several epitopes of an antigen, pAbs can be 
consistently used against highly mutagenic targets, like viruses, in analysis assays such as 
immunoprecipitation and enzyme-linked immunoassay (ELISA), considering not only their multiple 
epitope binding capabilities but also their usefulness as secondary anti-species antibody conjugates 
and binding effectiveness, even when covalently linked to a fluorochrome 42.  
When it comes to diagnosis and research methods, mAbs are an essential piece in many 
established techniques, and generally more used than pAbs, due to their more specific nature and 
standardization of mAbs produced from hybridomas or cell cultures 52. Since the development of a 
competitive binding assay using a radioisotope, by Yalow et al. 53, and after the design of the first 
ELISA quantitative assay by Engvall et al. 54, antibodies have proven to be a major scientific tool. 
The assays reliant on antibodies mostly function by detecting specific targets, which can be 
scientifically exploited for many uses. Immunocytochemical and immunohistochemical techniques 
are clinically vastly used to detect diseases biomarkers in cells or tissues 55,56, while techniques like 
Western blot are more suited towards the detection and classification of proteins in a mixture 57. 
Besides the techniques focused on detection, some antibody-based methodologies also provide 
adequate tools for quantification, such as ELISA or radioimmunoassay 58,59, by specifically binding 
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to target antigens and then emitting a quantifiable signal, based on the concentration of the target. In 
addition to quantitative and detection applications, antibodies have an enormous potential for 
separation and purification, used in techniques like immunoprecipitation and immunoaffinity 
chromatography 60,61. There are also some antibody-based techniques that are more flexible, making 
their use possible for many applications. Some notable examples include immuno-polymerase chain 
reaction methodologies, that can provide both sensitive real-time detection and quantification of 
proteins 62. Another very flexible technique is flow cytometry, where antibodies serve as labels for a 
high number of cells that can then be processed by flow cytometry, capable of recording quantitative 
and qualitative information, thus enabling cell counting and sorting procedures 63. 
 
1.3. Immunoglobulin Y (IgY): an avian antibody 
The term IgY emerged in 1969 when Leslie and Clem identified the egg-laying avian homolog 
of the IgG mammalian antibodies 64. The general structure of IgY is the same as IgG: composed of 
four polypeptides, with two identical heavy chains (Hc) presenting a molecular mass ranging from 
67 to 70 kDa each in IgY, in contrast to the 55 kDa of IgG 65, and light chains (Lc) with a molecular 
mass of 25 kDa each 13, that are held together by disulfide and covalent bonds in a Y shape. Each arm 
of the “Y”, the antigen-binding fragment (Fab), contains a binding site responsible for the antigen 
binding, and the tail of the “Y”, the crystallizable fragment (Fc), imparts the antibody with its effector 
functions, such as pathway activation 47. An important difference between IgY and IgG antibodies 
however exists. The number of constant regions (Cr) at the Hc in IgG is 3, while in IgY it is 4, 
explaining the molecular mass difference between IgG and IgY, 180 and 150 kDa, respectively 32. 
IgY also lacks a hinge region, rich in proline, threonine, and serine, that is normally present in IgG, 
responsible for connecting the Fc and the Fab region of the antibody and providing it with a lateral 
and rotational movement for an improved antigen binding 47. The IgY molecule may compensate its 
lack of a hinge region by the expression of proline and glycine residues near the boundaries of the 
Cr, spatially similar to where the hinge region appears in IgG 13. These referred structural differences 
are shown in Figure 1.  
Concerning their physicochemical parameters, IgY is more hydrophobic that IgG and its 
isoelectric point (pI) is 5.5, lower than that of IgG that fits within 6.1-6.5 66 67. Another important 
parameter to take into account, especially concerning the oral administration of antibodies, is their 
pH and temperature stability. In this regard, IgY is more sensitive than IgG to acid denaturation, 
rapidly losing its activity at pH values between 3 and 4 68. However, Lee et al. 68 found that the 
addition of sorbitol can almost completely suppress the acid-induced deactivation, even at pH 3. On 
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the other extreme of the pH scale, IgY has been found to stay active under severe alkaline conditions, 
up to pH 11, having nevertheless its activity severely diminished at pH 12 and higher values 69. 
Finally, and in terms of temperature stability, IgY is stable in aqueous solutions at temperatures up to 
60 ºC with the addition of sucrose 70. 
 
 
Figure 1 - Structural differences between IgY and IgG molecules 71. 
 
Being one of the three classes of antibodies that birds produce (IgA, IgM, and IgY), IgY is by 
far the most relevant in terms of concentration, making up about 75 % of the total serum antibody 
population of chickens 72. IgY antibodies also are transferred from hen to chick in the latent stage of 
egg development by receptor-mediated processes 73. This fact makes the chicken egg a great source 
of antibodies, not only compared to the chicken’s serum 72, but also compared to others mammals 
serum, showing a per weight productivity 18 times higher than rabbit serum, for instance 74. Besides 
their higher production, there are other significant advantages connected to IgY, such as the 
antibodies production methodologies. The production of IgY requires only the collection of eggs, 
providing thus a more ethical and healthy treatment of animals than the traditional methodology used 
to obtain IgG where a significant amount of blood is necessary (obtained by repeated bleeding or 
heart puncture, possibly resulting in animal death) 17. Furthermore, chickens not only tolerate the 
immunization process better than rabbits 17, but are also easier to house 75, whereas the process for 
their immunization and collection of eggs is already well established on an industrial scale. 
9 
 
In terms of functionality, the use of IgY has significant advantages that make it very useful, 
especially regarding their use in immunoassays, where the phylogenetic difference between birds and 
mammals plays an important role, making of avian antibodies better suited for detection and binding 
with very conserved proteins in mammals 76. One specific case is the detection of proteins associated 
with human pregnancy, in which immunological cross-reactivity could not be achieved with rabbit 
or goat anti-serum, whereas it is possible with avian antibodies 77. This phylogenetic difference can 
be further exploited by looking at the fact that avian antibodies do not show cross-reactivity with 
rheumatoid factors, enabling the monitoring of acute phase proteins expression as a response to 
inflammatory processes, like in rheumatoid patients, that cannot be achieved with mammalian 
antibodies because of cross-reactivity 78. Further examples of the application of IgY, due to the 
inherent phylogenetic difference, lie in its lack of cross-reactivity with human antibodies 79. Another 
large contributor to interferences in immunoassays is the activation of the complement system 80, that 
can bind to mammalian antibodies and block the antigen-binding site 81, something that does not 
occur when avian antibodies are used 80. In spite of these advantages it is important to refer that 
antibodies can be humanized 82, normally using recombinant technology 83; yet, these processes 
require more time, manpower and monetary expense that could, in some cases, be avoided by using 
avian antibodies. For the reasons referred above, the use of IgY in immunoassays and 
immunodiagnostics has been reported and reviewed thoroughly 84. In spite of its lack of popularity, 
IgY is suited for practically all common immunologic methods 85, mainly because IgY can form 
conjugates with typical molecules used in these methods, like horseradish peroxidase or biotin 86,87. 
Some notable cases include its use in a fluorescence polarization immunoassay 88, rocket 
electrophoresis 89 and antigen-capture ELISA 90. 
In addition to their notable advantages for immunoassays, avian antibodies also have amazing 
prophylactic capacities that can be tapped by exploiting the process of passive immunization. Passive 
immunity, described in detail in the previous chapter, refers to the process of providing preformed 
antibodies for immediate but short-lived protection, lasting several weeks to three or four months at 
most. Therefore, passive immunity requires repeated or continuous administration and large amounts 
of antibodies 91, making hen antibodies more adequate for this type of application because of the 
relative easiness of production and acquisition. Concerning veterinary applications, IgY has been 
examined as a feed additive for livestock to both target pathogens, especially enteric, and to improve 
growth and feed efficiency 92. Some notable examples include the protection of pigs against E-coli 
infection by oral administration 93, the protection of newborn calves against Bovine rotavirus 94, and 
the reduction of immune-stimulating bacteria in the gut of animals by targeting molecules involved 
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in inflammation and animal growth, among other examples described in Table 1. When it comes to 
applications in human medicine, IgY has also proved its efficiency and viability, getting the 
designation of an orphan drug, an agent developed especially to treat a rare condition by the  European 
Medicines Agency, namely on their use in the prevention of Pseudomonas aeruginosa in the airways 
of cystic fibrosis patients 95. Other anti-bacterial effects of IgY include the suppression of Heliobacter 
pylori infection, a common cause of gastritis and gastric ulcers 96, and the reduction of the levels of 
Porphyromonas gingivalis 97 and Streptococcus mutans 98, responsible for plaque forming and tooth 
decay in humans.  
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Table 1 - Examples of IgY use in veterinary medicine (adapted from the literature 99). 
Pathogen/antigen Target Species Effects of IgY 
Escherichia coli 
Pigs Protection against infection 
Cattle Reduction of E. coli induced fecal shedding 
Chickens 
Improvement of intestinal health and 
immune response following bacterial 
challenge 
Humans Reduction of in vitro binding 
Salmonella spp. Chickens 
Reduction of fecal shedding and cecal 
colonization 
Bovine rotavirus 
(BRV) 
Cattle 
Protection of neonatal calves against BRV 
induced diarrhea 
Infectious bursal 
disease virus (IBDV) 
Chickens Protection of chicks from IBDV infection 
Eimeria spp. Chickens 
Protection of chicks against avian 
coccidiosis 
Porcine epidemic 
diarrhea virus (PEDV) 
Pigs Protection from PEDV infection 
Canine parvovirus Dogs 
Protection against CPV2-induced disease 
symptoms 
Heliobacter pylori Humans 
Reduction of bacterial growth, urease 
activity and gastric mucosal injury in animal 
model 
Suppressed infection in humans when 
incorporated in yogurt 
 
1.4. Conventional methods for the purification of antibodies 
There are many techniques for the production of antibodies, developed and improved over the 
years, involving ascites fluid 100, plasma cells 101, cell cultures 15, bacteria and yeast 102, transgenic 
plants 103, and egg yolk. All of these production techniques result in many different end products that 
contain the target antibodies, as well as other impurities, like cellular components and debris, DNA, 
lipids or other proteins. For this reason, the purification of antibodies is a very important step in the 
development of a successful platform of antibodies production, commercialization, and application.  
Many techniques for the purification of antibodies have been used, and even though chromatographic 
methods are the most commonly used, there are many other techniques that should be discussed. The 
most common technique used for proteins purification is chromatography, and as such, it is 
mandatory to take into consideration affinity chromatography, one of the most applied techniques 104. 
This technique is based on a reversible specific interaction of the target protein with a ligand, 
exploiting this specificity in order to separate the target compounds from a complex mixture. While 
there have been some efforts on the development of new types of ligands, protein-A is still the most 
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used 104. Protein A, a cell wall component of Staphylococcus aureus, binds selectively to IgG, by the 
antibody’s Fc regions, but binds weakly to human IgA or IgM 105, and the connection to IgY is almost 
negligible 106. Despite its high binding capacity for IgG, and as such its main use is for IgG 
purification, there are some major disadvantages with the use of protein A, namely the high 
manufacturing and processing costs, difficulties in scaled-up applications, limited life-cycles and, 
since the production of these types of ligands is achieved through bacteria, there is a risk of 
contamination by viruses, pyrogens and DNA 104. 
Another kind of chromatographic technique used for the purification of antibodies is ion-
exchange chromatography, which includes anion exchange chromatography (AEC) and cation 
exchange chromatography (CEC). AEC has been a focal point of scientific innovation due to this 
technique importance for the removal of DNA, virus, endotoxin, leached protein-A and acidic host 
cell protein contaminants, being one of the most flexible tools in chromatography 107. When it comes 
to chromatography it is necessary to distinguish between two main modes: bind elute, where the 
sample elements are bounded to the column, and flow through, where the column contents are flushed 
along with the solvent 108. Bind elute AEC is useful when the sample contains impurities that bind 
less strongly to the used column, like in the case of murine IgG 109. Flow through chromatography is 
more favorable when the antibodies bind weakly or not at all to the column, as is the case with human 
and chimeric IgG 109. The flow-through mode is commonly conducted on membrane exchangers, 
since they are less expensive and provides a higher throughput than porous particles, without 
compromising the DNA or virus removal 110, with the host-cell protein removal usually being the 
limiting factor. In light of this fact, there have been studies detailing the use of displacement 
chromatography, where the antibody is loaded continuously in conditions where it binds weakly to 
the column, achieving more than 99 % of host cell protein removal, with a high ratio of antibody 
processed per liter of membrane 111. On the other hand,  with the introduction of new porous particle 
ion exchangers, there has been an interest in using CEC as a substitute for protein-A capture 112. There 
are significant cost and cleaning advantages and high binding capacities 112; however, the pH control 
has proved to be a challenge for the elution process for CEC 113. When salt gradient elution is utilized, 
ions like sodium have a higher affinity for exchange groups than hydrogen ions, causing a 
displacement of hydrogen to the mobile phase, and consequently a pH drop 113.  
When it comes to non-chromatographic methodologies, the discussion of filtration-based 
methods is of utmost importance. These techniques have maintained the interest of the scientific 
community, despite its industrial application being reliant on bulky and expensive hardware when 
some kinds of membrane filtration systems are used 114. Although the high costs associated with this 
13 
 
technique, there are some examples of successful scale-up applications using cross-flow filtration for 
cell cultures 115. Van de Reis et al. 116 developed a technique based on cross-flow filtration, yet using 
a charged ultrafiltration membrane that, via ion exclusion, repels positively charged proteins such as 
mAbs. As mAbs are small enough to pass through the pores, they are retained and concentrated, while 
alkaline, neutral and weakly acidic contaminants are released, and strongly acidic contaminants may 
be retained 116. This technique can present some disadvantages since, at membrane conductivity 
values low enough to repeal antibodies, positively charged surfaces can bind DNA that, if present at 
a high enough concentration, can reduce the membrane’s potential, thus significantly impairing the 
processes’ effectiveness 117. Utilizing this technique as a secondary step to other processes might 
solve this contamination problem, one example of which being co-precipitation. The use of positively 
charged polymers has led to the selective precipitation of acidic host proteins, DNA, and various other 
culture additives, and a multistep purification process using polyallylamine has led to results 
competitive with those obtained with protein-A based chromatographic processes 118.  
 
1.4.1. IgY purification methods 
To obtain pure IgY from egg yolk there are two crucial steps: (i) removal of the lipids and 
lipoproteins, obtaining a water-soluble protein fraction (WSPF); and (ii) purification of IgY from the 
WSPF which contains a large number of water-soluble proteins. One of the most used techniques for 
lipids removal from egg yolk, is water dilution, as proposed by Kwan et al. 119. Further research by 
Akita et al. 120 led to an optimum recovery from 93 to 96 % of IgY by exploring a 6-fold water dilution 
at pH 5.0 and incubating the sample for 6 h at 4 ºC. Another methodology that is also simple consists 
on freezing and thawing the egg yolk samples, introduced by Jensenius et al. 121, who explored the 
aggregation of yolk lipids at neutral pH after a 9 volume water dilution and a freezing and thawing 
cycle, finally recovering the antibody by centrifugation 121. Even though both of these processes have 
some disadvantages considering the increase of sample volume, and thus increasing the storage and 
handling requirements, the simplicity and cost can, in some cases, outweigh these drawbacks. 
Jensenius et al. 121 used a modified process for the separation of lipoproteins 122, achieving better 
results using dextran sulfate on a buffer-diluted yolk solution and then adding calcium chloride to 
precipitate the dextran in excess, followed by incubation at room temperature and centrifugation 121. 
Other similar precipitation approaches include the use of phosphotungstic acid and magnesium 
chloride 123, and polyethylene glycol (PEG) 67. The use of volatile organic solvents has also been 
explored, with some researchers utilizing propane-2-ol and acetone in a series of cycles of 
continuously-stirred mixing, followed by the collection of the resulting powder and its dissolution in 
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a buffer, finally recovering the proteins by centrifugation 124. A comprehensive comparison of the 
lipids removal capacities of the referred processes revealed that the highest protein yields were 
obtained via methods based on the combination of polyanions and cations, the dextran sulphate and 
the phosphotungstic acid methodologies, achieving average IgY yields of 15.6 and 15.1 mg per mL 
of yolk, with purities of 64.3 and 69.8 %,  respectively 125. The simpler process of freezing and 
thawing at neutral pH led to IgY recoveries of 13.1 mg per mL of yolk, being this process the one 
that resulted in the highest purity level (71.1 %). The remaining two processes resulted in a low purity 
end product, capping their effective IgY yield at only 11.0 mg per ml of yolk, in the case of PEG 
precipitation, and 7.11 mg per ml of yolk for the propane-2-ol and acetone technique 125. 
After the initial delipidation step, the obtained WSPF is then processed in order to be 
concentrated and further purified, normally using a combination of several techniques, which can be 
grouped into three types: precipitation, filtration and chromatographic techniques 19. Akita and Nakai 
120 showed the recovery and purity percentages of IgY after several stages of purification from the 
WSPF, starting with the precipitation with ammonium sulfate, followed by either ethanol 
precipitation at sub-zero temperatures or ultrafiltration, with a final chromatographic step using either 
AEC or size exclusion chromatography. These researchers found that while just the salt precipitation 
procedure was insufficient to obtain a pure sample, reaching only 30 % of purity, following it with 
the sub-zero temperature ethanol procedure or ultrafiltration could lead to high purity samples of over 
93 % 120. Following either of these techniques with Diethylaminoethyl–Sephacel, a kind of AEC, or 
gel filtration with Sephacryl S-200 led to even greater purities, over 99 % 120. Deignan et al. 125 
observed that the best precipitation method, when compared to ammonium sulfate and sodium sulfate 
salt precipitation, was the one developed by Polson et al. in 1985 126, using 12 wt % of PEG 8000 
followed by its removal with sub-zero ethanol. Kim and Nakai 127 demonstrated the possibility of 
scaling-up the IgY purification methods by utilizing several ultrafiltration systems on a WSPF 
delipidated using an octadecyl column after filtration with a cellulose powder column. They achieved 
a high IgY purity with all the systems tested, the best being the Amicon, reporting an IgY purity of 
99 % and a recovery of 80 % 127. An earlier publication by the same group 128, demonstrated purity 
levels over 90 % and a recovery of about 92 % of IgY, with the key methodologic difference being 
the use of the freeze and thaw method to obtain the WSPF, a cheaper and easier process when 
compared to the delipidation method used in their other work 127. Lastly, but possibly the most used, 
are the chromatographic techniques used for IgY purification, even though they can be rather 
restricted if the sample is too complex 129, making it necessary to couple this technique with others. 
Fichtali et al. 130 achieved about 60 % of purity for IgY from a WSPF produced via the water dilution 
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method, using an HC-2 medium CEC. The process was then coupled with a salt precipitation process 
using 15  wt % of sodium sulfate, improving the sample’s purity up to 90 %; yet, this technique leads 
to low recoveries (50 %) 130. The purification techniques presented above all require some 
performance and quality compromises for monetary and simplicity advantages, or vice versa. 
Therefore, there is no end-all technique available for IgY purification that can be effective, cheap and 
able to be scaled-up. In this sense, there is a growing need to focus on unconventional and cost-
effective techniques – a goal of this work, described in more detail in the following sections. 
 
1.5. Aqueous Biphasic Systems (ABS) 
The introduction of Aqueous Biphasic Systems (ABS) by Albertson 26 in the 50’s 
revolutionized the field of liquid-liquid extractions 131,132 . ABS have several significant advantages 
over typical solvents used for liquid-liquid extraction, mainly because they provide a milder 
environment for biomolecules purification afforded by their high water content and low interfacial 
tension, which translates into lower losses of structure and biological activity of the target product 
24,25. The other key advantage of ABS is their tunability since the phase forming components can be 
altered not only in chemical nature but also in composition to achieve ideal separation conditions 133. 
These aspects, coupled with the fact that this technique is relatively cheap and easy to be scaled-up 
134, make of ABS a very valuable tool for the purification of antibodies (e.g. IgY). 
The two-phase formation in ABS is achieved by mixing two polymers 135, a polymer and a 
salt 136, or two salts 137 in aqueous media above given concentrations. The choice of the phase forming 
components is a very delicate and critical step, as it dictates the distribution/partitioning of the target 
biomolecule between the coexisting phases 138. This solute/biomolecule partition coefficient can be 
exploited by manipulating the phase forming components weight and concentration, the ionic strength 
of the medium, the system pH and through the use of adjuvants 133,139. The composition of the ABS, 
i.e. the amount of phase forming components required to form two-phase systems, is usually taken 
from their phase diagrams – Figure 2 23. The so-called binodal curve of the phase diagram separates 
the monophasic and the biphasic regions. Another important information retained in the phase 
diagrams is the tie-line, that describe the composition of the two phases for a given mixture point 23.  
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Figure 2- Example of a phase diagram for a polymer/salt system, showing the binodal curve, a tie-line 
and three ABS corresponding to different mixtures in the same tie-line, (X, Y and Z). C= critical point; 
T=composition of the top phase, B=composition of the bottom phase 23. 
 
Concerning the use of ABS in biomolecules purification, there is an extensive number of 
examples including cells 140, viruses 141, and proteins 142, as a way to reduce the downstream 
processing time and costs associated. When it comes to antibodies, Eggersgluess et al. 143 
demonstrated that a polymer/salt ABS, composed of 12 wt % of PEG 400 and 28 wt % of phosphate 
buffer, was effective as a single-step wash and extraction procedure for mAbs from a complex cell 
culture broth. Azevedo et al. 144 provided evidence towards the use of ABS for the initial purification 
step of IgG from hybridoma cell cultures and Chinese Hamster Ovary cell supernatants, recognizing 
an ABS composed of 12 wt % of PEG 6000, 10 wt % of NaH2PO4/K2HPO4 buffer and 15 wt % of 
NaCl as the most effective, giving rise to 90 % of recovery yields and purification factors of 4.0. The 
same group 138 also used polymer/polymer ABS, composed of PEG 3350 and Dextran 500000 
modified with glutaric acid, to enhance the ABS purification yield by increasing the system’s affinity 
to IgG, recovering 97% of IgG with a purity of 94 %. Yau et al. 22, in their review, described a series 
of applications of ABS, showing also the difference between the different kinds of phase forming 
components used.  
 
1.6 Fast Centrifugal Partition Chromatography 
Fast Centrifugal Partition Chromatography (FCPC) is a type of liquid-liquid chromatography 
requiring two immiscible liquid phases, one of which acts as the stationary phase and the other acts 
as the mobile phase 27. The lack of a solid support distinguishes this technique from commonly used 
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chromatographic methods, like high-performance liquid chromatography, where a column with an 
adsorbent material is usually utilized 145. While the basis of this technique is indeed common to other 
liquid-liquid chromatographic methods - partition of solutes between the two phases formed, the 
notable difference between them and FCPC is the use of a centrifugal force by the later, in order to 
hold the stationary liquid phase 27. The concept of FCPC was introduced in 1982 by Murayama et al. 
146, stemming from an already established technique developed in 1944 by Lyman Craig 147, the 
countercurrent distribution (CCD), with the first functional FCPC instrument being manufactured by 
Sanki Engineering 148. A Sanki-type FCPC machine is composed of basic components, also 
encountered in most chromatographic systems, such as pumps for solvent delivery and valves to 
control them, a sample injector, a detector and a recorder, with the main difference between these and 
conventional systems being the rotor, the centerpiece of this equipment functionality 27. The rotor is 
composed of several stacked discs engraved with a great number of cell channels, with each cell 
linked to the following one by a small duct, where the stationary phase is retained, stabilized by the 
centrifugal field generated by the spin of the rotors 27. An example of this centerpiece can be found 
in Figure 3. The liquid nature of the applied phases and the mechanical construction of the FCPC 
apparatus allows for two modes of operation to be used, ascending and descending. The key 
difference in these modes is the density of the phase being used as the mobile phase: in the ascending 
mode the lightest phase is the mobile, flowing upwards through the heavier stationary phase, while 
the opposite occurs in the descending mode 149. A representation of the ascending mode of operation 
can be found in Figure 3. The FCPC apparatus operation involves the pumping of the stationary phase 
into the channels, while the rotor is working at low speed, usually between 300 to 600 rpm, followed 
by the introduction of the mobile phase 27. The FCPC system is usually cleaned with water and as 
such, in order to begin a new FCPC extraction, all of the water needs to be pumped out, something 
that is achieved by pumping an amount of stationary phase that can completely fill the FCPC cell 
channels, replacing the water that was inside. To make sure that the system is completely filled with 
the stationary phase it is necessary to collect a significant amount of the stationary phase, usually a 
volume corresponding to the total column volume. Only after this process can the pumping of the 
mobile phase be initiated and, after that, the sample can be introduced. 
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Figure 3 - Upper inside view of a pilot-scale Sanki FCPC 148 and a representation of the FCPC’s 
ascending mode of operation, with the lighter mobile phased rising through the denser stationary 
phase 150. 
 
FCPC works by the exploitation of the partition trend of different compounds between the 
two immiscible solvents/phases, as long as their densities are sufficiently different 27. The main 
advantage of using FCPC comes from the liquid-liquid nature of this process, making it unnecessary 
to use solid chromatographic supports, guaranteeing therefore almost 100 % of the target compound 
recovery and an easy recyclability of the solvents, thus minimizing environmental problems 27, while 
also avoiding the need to buy, maintain and clean high-cost solid columns 149. The high volume of 
the stationary phase that can be loaded into the FCPC is also a significant advantage, making this 
technique very suitable for industrial applications 150. While this adaptability is seen as an advantage 
in terms of potential applications, it should be stressed the importance of a careful choice of the 
solvents/phases, which should be defined according to the following criteria: easiness of two-phase 
formation; capacity to be retained by the FCPC; and separation/purification effectiveness 150. Even 
though the selection of a solvent system for use in FCPC can be in many ways similar to other 
chromatographic methods, when it comes to criteria such as polarity, charge state, and complexation, 
one also has to take into account the partition coefficients of the sample in that particular system 27. 
While the tweaking of classical chloroform/methanol/water or n-hexane/ethyl acetate/methanol 
proportions can be a good starting point, allowing for some manipulation of the system’s polarity in 
order to achieve the required sample distribution 27, there has been a major interest in utilizing ABS 
in FCPC. This increase is not only due to the ABS already outlined advantages in terms of tunability 
144, a characteristic that is essential for the development of a good FCPC separation protocol, but also 
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because of the high biocompatible environment that ABS provide, especially when compared to 
common organic solvents that, in many cases, induce conformation changes in proteins 25,151.  
While the separation capacity of the ABS is a really important parameter to acknowledge and 
tune, the first point of order for a successful FCPC protocol is the retention of the used system in the 
FCPC chamber. Without a proper retention and a minimal bleeding-effect, even if theoretically an 
ABS system is very successful in separating biomolecules, it will not lend itself to use in FCPC. In 
light of this concern, Schwienheer et al. 151 developed some guidelines to ensure a sufficient system 
retention, achieved by analyzing the phase’s physicochemical properties, hydrodynamics and 
bleeding tendency of the phases of a PEG + NaH2PO4/K2HPO4 ABS 
151. Their main findings were 
that a low viscosity coupled with a high interfacial tension leads to the best stationary phase retention; 
however, an increase in density leads to an increase in the pressure drop 151. While these were found 
to be the best conditions, if partition performance of the target molecule is not sufficient, i.e. the 
protein is not partitioning selectively to just one phase, some changes might be in order. To overcome 
this drawback, Schwienheer et al. 151 recommended the use of a polymer with higher molecular weight 
and a decrease of the content of the phase forming components. When it comes to picking the mode 
of FCPC operation, the mode that allows the lightest phase to be the mobile one should be the 
preferred choice, meaning, in the case of most PEG + salt systems, the descending mode. The choice 
of rotational speed should simply be the highest allowed by the system, in order to increase the mass 
transport between the phases while not allowing a significant pressure drop 151. 
To further evidence the advantages of using FCPC for the separation/purification of 
biomolecules, it is important to look at previous cases of its successful applications. In recent years, 
FCPC has been used to isolate and purify many natural products, from phenolic compounds 
(chlorogenic acids) 152, terpenes (geniposide)  153, alkaloids (sinomenium) 154, and antibiotics 
(aldecalmycin) 155. Yoon et al.156 provided a review on the use of FCPC for the purification of many 
compounds, including works from 1994 to 2009, and that can serve as a follow-up to the examples 
presented here. In the case of protein extraction, while not yet a common mainstay in the subject, 
FCPC has seen also used. Foucalt et al. 157 successfully used FCPC to separate two membrane protein 
fragments, dubbed C1 and C2, utilizing FCPC with a three solvent system consisting of 
CH3COOH/HCOOH/CHCl3 and water at 800 rpm, with a flow rate of 1 ml/min, making use of 
different concentrations of CH3COOH and HCOOH to control the partitioning of the fragments from 
either 100 % on the bottom phase, in systems poor in HCOOH, or 100 % to the top phase, in systems 
rich in HCOOH. The separation of the two types of fragments was then achieved using reversed phase 
chromatography, for the HCOOH poor systems, or cation exchange chromatography for the HCOOH 
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rich systems, in which both methodologies the C2 fragments elute first. Another work on the 
separation of peptide fragments via FCPC was developed by Amarouche et al. 158, presenting two 
new solvent systems, composed of heptane/tetrahydrofuran/CH3CN/dimethyl sulfoxide/water and 
heptane/methyl-tetrahydrofuran/N-methyl-2-pyrrolidone/water, to be used at a 8 mL/min flow rate 
and 1400 rpm. These systems allowed for a recovery of 85.7 % with 98.7 % purity, for the first 
system, and a recovery of 71 % with 92.1 % purity for the second system, as determined by HPLC 
158. This work demonstrated the FCPC’s effectiveness at separating synthetic peptides used for the 
drugs Bivalirudin and Exenatide, whereas separation by HPLC had proven to be difficult 158. For the 
extraction of proteins, like laccases from fermentation broth, Schwienheer et al. 31 used FCPC with a 
buffered PEG 3000/NaH2PO4 ABS, at 1000 rpm with a flow rate of 5.0 mL/min, achieving a 
separation of highly active laccases, demonstrating that the use of ABS systems with FCPC can 
provide conditions for gentle separation of enzymes. Other applications have also marked the 
significance of FCPC protocols, as shown by Bérot et al. 159, who achieved purification rates of above 
95 % with much higher yields than other common methodologies for the preparative purification of 
pea albumin. These researchers used a n-butanol/water system at a 2.5 mL/min flow rate at both 500 
and 1200 rpm, acknowledging that while the difference in rotor speed did not affect purification 
results, the lower speed generated less pressure in the system 159. When it comes to antibodies, the 
focus of this work, Oelmeier et al. 160 presented FCPC as an alternative separation step that, when 
combined with other precipitation and resolubilization techniques, can purify monoclonal antibodies 
in an easily scalable manner, while providing a high concentration of target proteins with insignificant 
contamination. These researchers found that after removing the cells from a culture supernatant, either 
via regular means like centrifugation or by using liquid-liquid separation approached by ABS, and 
performing a FCPC run in dual-mode, an upper phase rich in antibodies could be attained while 
removing host cell proteins 160. The solute system used in the FCPC run was PEG 400/Citrate, at 
21.02 % and 18.99 wt % %, determined by an high-throughput development approach introduced by 
the same authors 29. Testing several operational parameters, in terms of flow rate and rotation speed, 
they also found that the system’s retention capacity diminished with an increase in flow rate, and 
while the rotation speed did not significantly affect this parameter, the column’s back-pressure is 
heavily influenced by it 160. The FCPC run was performed at a 5 mL/min flow rate and 1500 rpm, 
achieving a compromise between functional speed and effectiveness. This extraction step, done via 
FCPC, was then combined with a subsequent precipitation of the antibodies by addition of PEG 4000. 
After this step, the precipitate was washed with a 3.0 pH citrate buffer, that not only removes the 
polymer but also provides a virus inactivation effect, in a process similar to what is performed by 
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protein-A affinity chromatography 160,161. In the end of this procedure, the clearance of host cell 
proteins surpassed 99 %, while still achieving an impressive 93 % recovery of antibodies 160. Despite 
these remarkable results, no more literature reports were found on this topic. 
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2. Experimental section 
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2.1 Aqueous biphasic systems: PEG 1000 + phosphate salt + H2O 
2.1.1 Chemicals 
The ABS studied in this work were prepared using an aqueous solution of PEG with a 
molecular weight of 1000 g/mol (PEG 1000), supplied by Fluka. The phosphate buffer used is 
composed of potassium phosphate dibasic trihydrate (K2HPO4·3H2O, purity > 99%) and 
monopotassium phosphate (KH2PO4, purity > 99.5%), acquired from PanReac and Sigma-Aldrich, 
respectively. The phosphate buffer was prepared at different pH values using different molar ratios 
of the two phosphate-based salts: 5.5 (±0.22), 6.0 (±0.16), 6.5 (±0.16), 7.5 (±0.02) and 8.0 (±0.05). 
The unbuffered aqueous solution was prepared using only K2HPO4·3H2O (pH value ca. 9.0). The 
water utilized was double distilled, treated with a Milli-Q plus 185 water purification apparatus. 
 
2.1.2 Experimental procedure 
2.1.2.1 Ternary phase diagrams 
The binodal curve of each phase diagram was determined through the cloud point titration 
method at 298 K (± 1 K) and atmospheric pressure 162. The phase diagrams were determined using a 
solution of PEG 1000 at 60 wt %, and aqueous salt solutions with different concentrations, detailed 
in Table 2. The repetitive drop-wise addition of each aqueous salt solution to the PEG 1000 solution 
was carried out until the detection of a cloudy biphasic solution, followed by the drop-wise addition 
of water until the detection of a monophasic region, limpid solution (direct method). To obtain a well-
defined phase diagram, the inverse approach was performed for all systems, with two exceptions – 
unbuffered systems and the one composed of the buffered salt solution with a pH value of 5.5. To 
this end, the repetitive drop-wise addition of the PEG 1000 aqueous solution to each aqueous salt 
solution was carried out until the detection of a cloudy biphasic solution, followed by the drop-wise 
addition of water until the detection of a monophasic region. Dropwise additions were carried out 
under constant stirring. The ternary systems compositions were determined by the weight 
quantification of all components added within an uncertainty of ± 10-4 g. 
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Table 2- Concentration of the initial phosphate salt solutions used for the phase diagrams 
determination of the ABS composed of PEG 1000 + phosphate salt + H2O. 
Phosphate salt solution / pH 
Concentration of salt (wt %) 
Direct Method Inverse Method 
5.5  26 n.d. 
6.0  35 35 
6.5  33 50 
7.5  32 60 
8.0  31 60 
Unbuffered 39 n.d. 
* n.d.: non-determined 
 
2.1.2.2. Determination of tie-lines and tie-line lengths 
The tie-lines (TLs), representing the composition of each phase for a given initial mixture 
composition, was determined by a gravimetric method originally described by Merchuk et al. 163. A 
previously selected mixture at the biphasic region was prepared, vigorously stirred, and allowed to 
reach the equilibrium by the separation of both phases for at least 4 h at (298 ± 1) K. Each phase was 
separated and the top and bottom phases were weighted. Finally, each individual TL was determined 
by the application of the lever-arm rule.  
The experimental binodal curves were fitted using Equation 1 163; 
 
[𝑃𝐸𝐺]  =  𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]0.5)  −  (𝐶[𝑠𝑎𝑙𝑡]3)]       (1) 
 
where [PEG] and [salt] are the polymer and phosphate solutions weight fraction percentages, 
respectively, and A, B, and C are fitted constants obtained by least-squares regression. 
 For the determination of the TLs the following system of four equations (Equations 2 to 5) 
was used to estimate the concentration of polymer and salt at each phase ([PEG]PEG, [PEG]salt, [salt]salt, 
[salt]PEG), 
 
[𝑃𝐸𝐺]PEG  = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
0.5 ) – (𝐶[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
3 )]      (2) 
 
[𝑃𝐸𝐺]𝑠𝑎𝑙𝑡  =  𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
0.5 ) – (𝐶[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
3 )]      (3) 
 
[𝑃𝐸𝐺]PEG  = 
[PEG]𝑀
∝
 - 
1−∝
∝
 [PEG]salt        (4) 
 
[𝑠𝑎𝑙𝑡]PEG  = 
[salt]𝑀
∝
 - 
1−∝
∝
 [salt]salt        (5) 
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where the subscripts “salt” and “PEG” correspond to the salt and polymer-rich phases, respectively, 
and M is the initial mixture composition. The parameter α is the ratio between the weight of the top 
phase and the total weight of the mixture. The solution of the described system provides the 
concentration of the polymer and salt in the top and bottom phases. 
 In order to calculate each tie-line length (TLL), Equation 6 was applied: 
 
TLL= √([𝑠𝑎𝑙𝑡]𝑃𝐸𝐺  −  [𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡)2 + ([𝑃𝐸𝐺]𝑃𝐸𝐺  −  [𝑃𝐸𝐺]𝑠𝑎𝑙𝑡)2    (6) 
 
The correlation parameters of Equation 1 and the compositions of the top and bottom phases, 
were determined using the software Matlab R2015a. 
 
2.2 Purification of IgY from egg yolk  
2.2.1 Chemicals and materials 
The water-soluble protein fraction (WSPF) of the egg yolk was obtained from fresh eggs, provided 
by Dr. Ricardo Pires from Biocant – Associação de Transferência de Tecnologia, Cantanhede, 
Portugal. The water-soluble protein fraction (WSPF) of the egg yolk was prepared following a 
protocol described by Liu et al. 164. A commercial kit (ABIN410202) from EggsPure IgY was used 
to purify IgY in order to determine the calibration curve to calculate the concentration and purity of 
IgY in each phase of the ABS. The ultrafiltration filters used (Amicon Ultra-0.5 mL), with a molecular 
weight limit of 100 kDa, were provided by Merck. The water employed was double distilled, and 
treated with a Milli-Q plus 185 water purification apparatus. The polymer and salts used are described 
in section 2.1.1.  
 
2.2.2 Experimental procedures 
2.2.2.1 Preparation of ABS  
The composition of the ABS used was chosen by the analysis of the phase diagrams. The 
mixture points selected are composed of 18 wt % of PEG 1000 + 15 wt % of phosphate-based salt + 
67 wt % of WSPF and 18 wt % of PEG 1000 + 13 wt % of phosphate-based salt + 69 wt % of WSPF. 
All components of the ABS were stirred at a moderate speed in a VWR vortex mixer until the solution 
turned cloudy, and left to rest for 4 h at (298 ± 1) K, to achieve the complete partitioning of IgY and 
contaminant proteins between the two phases. In all the mixtures evaluated, and at the compositions 
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used, the PEG-rich aqueous phase was the top phase while the salt-rich aqueous phase was the bottom 
phase. The pH values of the phosphate buffer solutions were additionally determined at (298 ± 1) K, 
using a METTLER TOLEDO SevenMulti pH meter with an uncertainty of ± 0.02. 
 
2.2.2.3. Quantification of IgY by Size-Exclusion HPLC (SE-HPLC)  
After a careful separation of the ABS phases, SE-HPLC, using a Chromaster HPLC (VWR 
Hitachi), was used with the aim of quantifying IgY in each phase, as well as to determine its purity. 
A calibration curve was determined for this purpose, shown in Appendix A (Figure A 1), using pure 
IgY obtained from a commercial kit, EggsPure IgY. A phosphate buffer solution (1000 mL) was 
prepared using 47 mL of a Solution A (27.8 g NaH2PO4), 203 mL of a Solution B (53.65 g 
Na2HPO4∙7H2O) and 35 g of NaCl. Each phase was diluted at a 1:9 (v:v) ratio in this phosphate buffer 
solution before injection. The SE-HPLC was performed on an analytical column Shodex Protein KW-
802.5 (8 mm x 300 mm). A 100 mM phosphate buffer + NaCl 0.3 M solution was run isocratically 
with a flow rate of 0.5 mL.min-1. The column oven and autosampler temperatures were kept at 298 K 
and at 283 K, respectively. The injection volume was 25 μL. The wavelength was set at 280 nm using 
a DAD detector. The obtained chromatograms were treated and analyzed using the PeakFit v4 
software. The partition coefficients of contaminant proteins, Kcont, were calculated according to 
equation 7, where [Contaminant]PEG and [Contaminant]salt correspond to the concentration of each 
contaminant protein in the polymer- and salt-rich phase, respectively. 
 
KCont = 
[𝐶𝑜𝑛𝑡𝑎𝑚𝑖𝑛𝑎𝑛𝑡]𝑃𝐸𝐺
[𝐶𝑜𝑛𝑡𝑎𝑚𝑖𝑛𝑎𝑛𝑡]𝑠𝑎𝑙𝑡
         (7) 
 
 
The extraction yield of IgY, YieldIgY (%), was calculated according to equation 8, where mPEG and 
mWSPF are the mass of the top phase and the mass of WSPF added to the system, respectively, with 
[IgY]PEG and [IgY]WSPF being the concentration of IgY in the top phase and in the WSPF added to the 
system, respectively.  
 
 
YieldIgY (%)  = 
𝑚𝑃𝐸𝐺 x [𝐼𝑔𝑌]𝑃𝐸𝐺
𝑚𝑊𝑆𝑃𝐹 x [𝐼𝑔𝑌]𝑊𝑆𝑃𝐹
 x 100       (8) 
 
The IgY purity, PurityIgY (%), in the top phase was calculated according to equation 9, 
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PurityIgY (%)  = 
[𝐼𝑔𝑌]𝑃𝐸𝐺
[𝐼𝑔𝑌]𝑃𝐸𝐺 +[𝐶𝑜𝑛𝑡𝑎𝑚𝑖𝑛𝑎𝑛𝑡𝑠]𝑃𝐸𝐺
 x 100      (9) 
 
2.2.2.4. Fast Centrifugal Partition Chromatography (FCPC) 
A Fast-Centrifugal Partition Chromatography (FCPC)® system, model FCPC-C, from 
Kromaton Rousselet-Robatel (Annonay, France), was used for the IgY purification. The equipment 
design comprises a pattern of cells interconnected by ducts and dug in a stainless steel disk. The cell 
design, also called as twin cells, contains a restriction in the middle ducts of the canal creating two 
superimposed chambers. The total cell volume was about 50 mL, with 10 mL or 20 % of the column 
volume corresponding to the connecting ducts. The maximum theoretical liquid stationary phase 
retention factor (Sf = VS/ VC) was 80 % since 20 % of connecting ducts volume can only contain the 
mobile phase. The maximum rotor rotation was 3000 rpm, generating a maximum centrifugal field 
of ~ 1500 G. Two rotating seals, located at the rotor entrance and exit, can withstand a maximum 
pressure of 70 bar (7 MPa or 1000 psi). The FCPC system was connected to an ECOM ECB2004 
Gradient box with degasser, an ECOM ECP2010 Analytical HPLC pump, an ECOM Flash 14 DAD 
detector (four wavelengths were simultaneously being analyzed), and to a continuous scan (ECOM 
spol. S.r.o., Czech Republic). Several fractions were collected with an ADVANTEC® Super Fraction 
Collector CHF122SC (Advantec Toyo Kaisha, Ltd., Tokyo, Japan). Each sample was manually 
injected using a Rheodyne valve model 3055-023 using a 10 mL sample loop. Analogical detector 
signals were processed using the ECOMAC software (ECOM spol. S.r.o., Czech Republic). 
The FCPC assays were carried out using the system composed of 18 wt % of PEG 1000 + 13 
wt % of phosphate buffer at pH 6.0 and 67 wt % of water. This system was set to work in the ascending 
mode. The rotor was entirely filled with the bottom-rich phase at 600 rpm to achieve the homogeneous 
solvent re-equilibration on the rotor. Then, the rotation was set to the intended speed, needed for the 
appropriate stationary phase retention. After the working rotational speed was set up, the PEG 1000-
rich (top) phase was pumped through the stationary phase to reach the equilibrium.. The stationary 
phase retention, Sf, was calculated by the ratio of the stationary phase volume (VS) and the column 
volume (VC), as described in equation 10,  
 
Sf  (%) =  
Vs
𝑉𝑓
 x 100          (10) 
 
The sample loop was filled with 8 mL of WSPF and 2 mL of polymer-rich phase from the 
ABS composed of 18 wt % of PEG 1000 + 13 wt % of the phosphate buffer at pH 6.0 and 67 wt % 
water. 
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2.2.2.5. Ultrafiltration 
Ultrafiltration was performed on the most promising ABS, composed of 18 wt % PEG 1000 
+ 13 wt % phosphate salt buffer at 6.0 pH + 69 % WSPF, as an alternative purification technique to 
FCPC. The top phase of the ABS was collected and placed in. The filters were then placed inside an 
appropriate Eppendorf and centrifuged at 14,000 g for the duration of 6 cycles, 15 min each. Between 
each centrifugal cycle, the filtrate found in the filter exterior was collected and analyzed by SE-HPLC, 
also adding 300 µL of phosphate buffer to the filter interior. The final concentrate was mixed with 
200 µL of phosphate buffer and analyzed with SE-HPLC. Figure 4 describes the ultrafiltration 
process.  
 
 
Figure 4- Schematization of the ultraperformance assay 165. 
 
2.3. IgY Stability 
2.3.1 Chemicals and materials 
The IgY stability was evaluated in different aqueous solutions of phosphate-based salts and 
PEG 1000. The chemicals used were described in section 2.1.1. Pure IgY obtained from the 
commercial kit (ABIN410202), from EggsPure IgY, was used for comparison purposes. Circular 
dichroism spectra were recorded on a JASCO J-1500 spectropolarimeter (JASCO, Hiroshima, Japan). 
The ELISA assay was done using an IgY ELISA Kit obtained from Abnova Corporation, Taiwan, 
containing a dilution solution, wash solution, an anti-IgY-HRP conjugate, a chromogenic substrate, 
the stop solution, an IgY calibrator. The ELISA microplaque was analyzed in a BioTeck Synergy HT 
31 
 
microplate reader. The water utilized was double distilled, and treated with a Milli-Q plus 185 water 
purification apparatus. 
 
2.3.2 Experimental Procedure 
2.3.2.1 Circular Dichroism  
The IgY secondary structure was evaluated in different aqueous solutions by Circular 
Dichroism (CD). IgY (3 mg/mL) was mixed in a 1:1 w:w proportion with all of the following aqueous 
solutions: phosphate buffer at pH values of 5.5, 6.0, 6.5, 7.5, 8.0 and K2HPO4 at 26-36 wt %; PEG 
1000 at 10%, 20% and 30 wt%. IgY in the top phase of the following ABS was also analysed by CD 
for the following systems: 18 wt % of PEG 1000 + 15 wt % phosphate buffer at pH 6.0 + 67 wt % of 
the IgY aqueous solution; and 18 wt % of PEG 1000 + 13 wt % phosphate buffer at pH 6.0 + 69 wt 
% of the IgY aqueous solution. Standard samples of all the previously mentioned solutions were also 
prepared using water instead of the IgY solution. Circular dichroism spectra were recorded from 200 
to 260 nm using quartz circular dichroism cuvettes (0.1 cm) at room temperature (ca. 298 K). Each 
circular dichroism spectrum is the result of four accumulations recorded in millidegrees. The 
following acquisition parameters were used: data pitch, 0.5 nm; bandwidth, 1.0 nm; response, 1 s; 
and scan speed, 50 nm min−1. 
 
2.3.2.2 ELISA 
The top phase of the ABS composed of 18 wt % of PEG 1000 + 15 wt % phosphate buffer at 
pH 6.0; the concentrated rich fraction in IgY obtained by ultrafiltration; and the highest IgY purity 
fraction obtained from FCPC were analyzed by ELISA. The IgY standards were prepared according 
to the indication provided by the kit’s manufacturer. Using the provided calibrator, standard solutions 
were prepared at  concentrations of 400, 200, 100, 50, 25, 12.5, 6.25 and 0 ng/mL, using the ELISA 
dilution solution. All samples and standards were added to the microplaque wells in duplicate, 
forming IgY-Anti IgY complexes due to the Anti-IgY adsorbed in them. After 30 min of incubation, 
the wells were aspirated and washed with the provided washing solution in order to remove all 
proteins that did not form complexes. The anti IgY-HRP conjugate was then added to the wells, 
binding to the previously recognized IgY. After 30 min of incubation the wells were washed again 
and the chromogenic substrate, 3,3’,5,5’-tetramethylbenzidine (TMB), was added, allowing the HRP 
enzyme to catalyze the chromophoric reaction. Following 10 min of incubation, the provided stop 
solution was added and the samples absorbances were measured at 450 nm - calibration curve given 
in Appendix E (Figure E 1).  
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3. Results and Discussion 
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3.1 Evaluation of the FCPC operational parameters and system 
composition 
As described in section 1.6, there are three main parameters that should be analyzed for the 
selection of a proper solvent to be used in FCPC: the easiness of two-phase formation; the retention 
capacity in the FCPC cells; and the separation/purification effectiveness 150,151. The first and most 
pressing characteristic for any prospective solvent system is its retention capacity in the FCPC cells. 
In order to move on with an adequate system composition ensuring a minimal bleeding out effect, a 
literature review was previously carried out, summarized in Table 3. 
 
Table 3 - ATPS used in FCPC to separate proteins. 
Components 
Concentration 
(wt %) 
Flow Rate / 
(mL min-1) 
Rotation 
/ (rpm) 
Extracted 
Protein 
Reference 
PEG 1000 12.50 
10.00 2000 
Lysozyme 
and 
Myoglobin 
Sutherland et al. 
166 K2HPO4 12.50 
PEG 400 21.02 
5.00 1500 
mAbs from 
cell culture 
Oelmeier et al. 160 
Na3C6H5O7 18.99 
PEG 1000 19.20 
0.45 1200 Ovalbumin Foulcault et al. 167 
(NH4)2SO4 14.50 
PEG 4000 13.00 
5.00 2000 
Cianovirin-
N from 
transgenic 
tobacco cell 
culture 
Grudzien et al. 168 
NaH2PO4 13.00 
PEG 3000 13.00 
5.00 1000 
Lacase from 
Pleurotus 
Sapidus 
culture 
Schwienheer et al. 
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K2HPO4 6.00 
NaCl 2.50 
 
Foucault et al. 167, in 1990, compared several polymer/salt and polymer/polymer ABS in 
FCPC assays, concluding that while all of the systems analyzed have an effective retention capacity, 
the major problem conveys in the mass transfer effect, requiring significant reductions in the 
apparatus’ flow-rate to overcome this effect. Advances in FCPC technology 148 have permitted the 
effective use of higher flow rates with polymer/salt ABS, as demonstrated by Sutherland et al. 166, 
using ABS formed by 12.50 wt % of PEG 1000 + 12.50 wt % of K2HPO4, with a 10.0 mL/min flow-
rate. This system was used in the first step of this work. This decision was based on the system’s 
previously portrayed effectiveness when it comes to retention 166, but also because of the remarkable 
results provided by this system for the purification of enzymes and proteins 169,170, including 
antibodies 171,172, and the work already done on the characterization of antibodies’ partition behavior 
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in this kind of ABS 173. It was however decided to use a lower flow rate, 1.5 mL/min, in order to 
establish a functional starting point in the FCPC’s operating parameters. This decrease in the flow 
rate was due to concerns of possible ineffective retention that could be exacerbated by running the 
assay at a higher flow-rate. While the compromise of a lower purification time in order to maintain 
adequate stationary phase retention was kept in mind, its limits were pushed by increasing the flow 
rate to 2.0 mL/min, with good results. Both the ascending and descending mode of FCPC operation 
were tested, maintaining the rotation value of 2000 rpm for the ascending mode used by Sutherland 
et al. 166, and then increasing it to 2500 rpm for the descending mode. In general, higher retention 
values seem to lead to a better system retention, as long as the apparatus’ pressure limit is not reached 
158.  
The process consisted of filling the column with the phase that would serve as stationary, the 
phase rich in PEG 1000 for the descending mode, and the phase rich in K2HPO4 for the ascending 
mode, and then pump the mobile phase to achieve the equilibrium between the phases. The stationary 
phase retention, shown in Table 4, was calculated by equation 10, achieving Sf values of 47.30 % and 
46.00 % for the ascending mode of operation at 2000 rpm, with 1.5 mL min-1 flow rate, and 48.52 % 
for the descending mode at 2000 rpm and with a 1.5 mL min-1 flow rate. An increase of the flow rate 
and rotation, to 2.0 mL min-1 and 2500 rpm, respectively, in the descending mode was also tested, but 
yielded the worst stationary phase retention, namely 44.90%. All the assays revealed to be well above 
the 20 % value that was deemed as the minimum adequate value for sufficient phase retention. This 
system composition has an effective retention, enabling its further use in this work, with slightly 
better results for lower flow rates and rotation speed, using the salt as a mobile phase in the descending 
mode. 
These assays provided a meaningful basis for further FCPC experiments, by testing the 
effective operational parameters and to determine a base ABS composition to be used in FCPC. An 
initial ABS was chosen from a literary review done on the subject, taking into account its retention 
in FCPC and its purification effectiveness. The 12.50 wt % of PEG 1000 + 12.50 wt % of K2HPO4 
ABS was tested in terms of retention, by changing several FCPC operational parameters, namely 
rotation, flow rate and operation mode (ascending/descending). All the operational conditions 
evaluated led to an effective retention of the phases inside the FCPC apparatus, as demonstrated by 
their Sf values of ≈46-49%, well above the 20% deemed adequate. In this sense, PEG 1000 and 
K2HPO4 were chosen to be used as components of ABS, with the system composition possibly 
benefiting from further tweaking to maximize extraction performance, as presented in following 
sections. The operational parameters evaluated did not show a significant negative impact when it 
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comes to system retention, demonstrating that the determining factor for the choice of effective 
operational conditions is not the retention but, possibly, the extraction performance. The impact of 
the operation conditions on extraction performance was evaluated in the subsequent sections. 
 
Table 4- Retention values achieved for the FCPC assays and their respective operational conditions. 
Sf (%) FCPC Operation Mode Rotation / (rpm) Flow Rate / (mL min-1) 
48.52 Descending 2000 1.5 
47.30 Ascending 2000 1.5 
44.90 Descending 2500 2.0 
46.00 Ascending 2000 1.5 
 
3.2 Aqueous biphasic systems: PEG 1000 + phosphate-based salt + H2O  
 After demonstrating that the selected system has a sufficient retention to be used in a FCPC 
assays, further optimizations of the ABS were carried out. To this end, phosphate buffer solutions at 
different pH values were prepared, namely 5.5, 6.0, 6.5, 7.5 and 8.0, in order to appraise the effect of 
the pH on the ABS extraction capacity. However, to address which compositions could be used, i.e. 
fitting within the biphasic region, the respective ternary ABS phase diagrams were determined at 298 
K and atmospheric pressure. The respective ternary phase diagrams are illustrated in Figure 5. The 
experimental weight fraction data of each phase diagram are given in Appendix B (Tables B 1 and B 
2). In the studied ABS, the top phase is the PEG-rich phase, while the bottom phase is primarily 
composed of salt and water.  
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Figure 5- Phase diagrams of the ABS composed of PEG 1000 + phosphate-based salt + H2O at 
different pH values: 5.5 (●); 6.0 (+); 6.5 (♦); 7.5 (▲); 8.0 (x); unbuffered (■). 
 
In the phase diagrams presented in Figure 5, the biphasic region, which corresponds to the 
area which leads to ABS formation, i.e. two phases, is located above the solubility curve. In general, 
there is an increase in the biphasic region area with the increase in pH, consequently meaning that the 
system’s capacity to form an ABS follows the trend: pH 5.5 < 6.0 < 6.5 < 7.5 ≈ 8.0 ≈ unbuffered. The 
separation of a polymer/salt aqueous solution into two phases is main a result of the salting-out effect 
of the salt over the polymer, in which ions that are more easily hydrated are more able to induce phase 
splitting 174. The main physicochemical characteristic associated with the salting-out ability is the 
ions' free energy of hydration, usually described according to the Hofmeister’s series 175. The 
Hofmeister’s series 176 rates ions according to their salting-out capacity, e.g. in the following well-
established orders: F- > SO4 
2-  > HPO4 
2-  >  C2H3O2
-> Cl-  and NH4 
+ > K+ > Na+ > Li+ > Mg 2+ (this is 
only a partial rank as many more ions were ranked). With the increase in the pH of the system there 
is a higher concentration of K2HPO4, and as such, higher concentrations of HPO4
2-, being this ion a 
stronger salting-out agent than H2PO4
-. This trend on the ABS behavior along the pH has been 
observed previously by Glyk et al. 177 on ABS of similar composition.  
The experimental binodal data were fitted according to the empirical relationship described 
by equation 1. The regression parameters A, B and C, which were estimated by the least-squares 
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regression method, are provided in Table 5, along with their corresponding standard deviations (σ). 
Overall, good correlation coefficients were obtained, indicating that these fittings can be used to 
predict data in any given region of the phase diagram, without the need to resort to experimental data. 
 
Table 5- Correlation parameters used to describe the experimental binodal data by equation 1, and 
respective standard deviations (σ). 
pH value A ± σ B ± σ 10-5 (C ± σ) 
5.5 99.2 ± 4.0 -0.49 ± 0.02 2.7 ± 2.0 
6.0 93.9 ± 2.0 -0.48 ± 0.01 7.5 ± 0.9 
6.5 97.9 ± 3.2 -0.49 ± 0.02 10.7 ± 1.2 
7.5 98.3 ± 3.5 -0.52 ± 0.02 15.2 ± 1.7 
8.0 98.4 ± 3.2 -0.53 ± 0.02 14.9 ± 1.5 
Unbuffered 92.4 ± 4.4 -0.51 ± 0.03 18.9 ± 4.4 
 
 The experimental data for the TLs and their respective length (TLL) are reported in Table 6. 
In Appendix C (Figures C 1 – 5) are reported the TLs for each ABS combined with the respective 
phase diagram. In general, the total composition of the system does not usually have a significant 
effect on the slope of the TLs. This implies that the TLs are generally parallel to each other, as 
presented in the example shown in Figure 6, allowing the phase compositions for any given system 
to be estimated. 
While the description of TLLs and the binodal data for the systems are important for further 
work using these systems, at the referred pH values, the main conclusion drawn from this section lies 
on the effect of pH on the binodal curve. In this sense, a clear correlation between the pH and the 
position of the binodal curve can be established, with higher pH values yielding systems with wider 
ranges of composition that present biphasic behavior.  
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Table 6- Weight fraction data for the TLs of the studied PEG 1000 + phosphate-based salt ABS. 
pH Value 
Weight Fraction Composition / (wt %) 
[PEG]PEG [salt]PEG [PEG]Mix [salt]Mix [PEG]salt [salt]PEG 
5.5 
3.935 37.812 15.011 17.913 18.861 9.200 
1.594 53.742 15.059 24.633 23.351 6.703 
6.0 
4.687 32.872 14.830 18.311 26.117 2.108 
2.765 42.115 14.904 24.859 32.021 0.524 
6.5 
4.415 34.376 14.961 17.854 25.470 1.391 
2.921 41.994 15.136 24.689 32.457 0.153 
7.5 
3.583 36.429 14.963 17.974 25.723 0.526 
2.398 43.797 14.979 25.048 31.761 0.040 
8.0 
3.268 37.816 14.855 18.317 25.375 0.612 
2.417 43.340 15.005 24.984 32.113 0.036 
Unbuffered 
2.779 39.549 15.034 17.978 25.034 0.376 
1.919 45.740 14.869 25.209 30.754 0.023 
 
 
Figure 6- Phase diagram of the ABS composed of PEG 1000 + Phosphate buffer at 6.0 pH + H2O: tie-
line data (●); adjusted binodal data obtained through equation 1 (−); experimental binodal data (■). 
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3.3 Purification of IgY from egg yolk using ABS 
3.3.1 Screening of the pH in ABS to purify IgY  
After describing the PEG 1000 + phosphate-based salts ABS by their phase diagrams, the 
mixture point for the extraction was selected to be composed of 18 wt % PEG 1000 + 15 wt % of 
phosphate-based salt, and 67 wt % of the WSPF prepared from egg yolk. This mixture point was 
selected to fit within the biphasic area of the phase diagram, but as close as possible to the binodal 
curve to maximize the water content on the system. Figure 7 shows the macroscopic appearance of 
the systems prepared, at different pH values. The appearance of these systems suggests that proteins 
in the WSPF suffer denaturation and precipitate, with a noticeable increase in the amount of 
precipitate found in systems with higher pH, with the unbuffered system also presenting some 
precipitation. Another important macroscopic characteristic is the precipitation of the K2HPO4 salt 
present in the ATPS at pH 5.5, as can be seen in Figure 7. 
 
 
Figure 7- ABS composed of 18 wt % PEG 1000 + 15 wt % Salt Buffer and WSPF, at several pH 
values. From left to right: 5.5 pH; 6.0 pH; 6.66 pH; 7.5 pH; 8.0 pH; Unbuffered. 
 
In spite of the precipitation of proteins, the purification effect of these systems cannot be ruled 
out, as the precipitated proteins can be contaminant proteins present in the WSPF. The occurrence of 
precipitation and denaturation of the proteins is due to the strong salting-out capacity of the salt used, 
and the amount of polymer added, as previously described in the literature 176,178 and better discussed 
in the next section – stability assays.  
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Both phases of the systems were collected and analyzed by SE-HPLC, without removing the 
precipitate in the interphase which was then discarded, in order to calculate the partition coefficients 
of the contaminant proteins, IgY recovery yield, and purity. The results obtained are shown in Table 
7 and Figure 8. The partition coefficient of IgY was not determined because, as can be seen in the 
chromatogram presented in Figure 9, as an example, no IgY peak was found in the bottom phase. 
This indicates a complete partition (selectivity) of IgY to the top phase (polymer-rich phase), in 
agreement with previous studies on the partition of other antibodies (IgG) in similar systems 173. In 
general, the values of the partition coefficients of the contaminant proteins to the polymer-rich phase 
tend to increase with the pH increase (Table 7), and thus, the selectivity of the system decreases with 
an increase in pH. The partition coefficients of the contaminant proteins are all above 1, meaning that 
the contaminant proteins are migrating mainly to the top phase, which in turn explains the relatively 
low purity of IgY obtained in a single-step with all systems. Overall, the pH value and/or the 
phosphate buffer used affects the purity of IgY, as extractions done at lower pH lead to the best 
results.  
While the extractions with phosphate buffers at pH 5.5 and 6.0 result in similar purity levels, 
the ABS composed of phosphate buffer at 5.5 is harder to form, resulting in some precipitation of the 
K2HPO4 salt, as shown in Figure 7, making this system less reliable to work with. Therefore, the ABS 
buffered to pH 6.0 was deemed more adequate, showing comparable purity and yield values, and thus 
further evaluated in ultrafiltration and CPC approaches.  
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Table 7 - Partition coefficients of contaminant proteins (Kcont1 and 2) present in the WSPF, and IgY 
purity and recovery yield using ABS. 
pH Value Purity ± σ (%) Yield ± σ (%) Kcont1 ± σ Kcont2 ± σ 
5.5 41.79 ± 0.12 89.10 ± 3.36 1.57 ± 0.04 1.44 ± 0.03 
6.0 41.07 ± 0.46 79.80 ± 3.09 2.04± 0.04 1.65 ± 0.12 
6.5 33.93 ± 3.58 79.88 ± 0.74 12.74 ± 8.83 2.52 ± 0.91 
7.5 27.19 ± 3.97 74.89 ± 3.41 10.75 ± 3.08 3.02 ± 0.66 
8.0 28.11 ± 1.60 79.93 ± 5.55 25.47 ± 12.35 3.54 ± 0.64 
Unbuffered 38.00 ± 5.78 89.64 ± 0.19 4.93 ± 0.87 6.07 ± 4.54 
 
 
 
Figure 8 - IgY purity (blue) and recovery yield (orange) from the WSPF of egg yolk using ABS at 
different pH values. 
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Figure 9 - SE-HPLC chromatograms of the top phase (orange) and bottom phase (blue) of the 
phosphate-based salt (pH 6.0) + PEG 1000 ABS. 
 
 
 
3.3.2 Screening of the mixture composition in ABS to purify IgY  
After the initial screening on the pH effect towards the IgY purification, different ABS mixture 
compositions, by changing the concentration of PEG 1000 and phosphate salt at pH 6.0, were tested. 
The phase diagram, presented in Figure 10, depicts three new mixture compositions were tested: 18 
wt %  PEG 1000 + 13 wt % phosphate salt buffer; 21 wt %  PEG 1000 + 16 wt % phosphate salt 
buffer; 21 wt %  PEG 1000 + 14 wt % phosphate salt buffer. The extraction results, in terms of purity, 
yield and partition coefficient of contaminant proteins are described in Table 8. 
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Table 8 - Partition coefficients of contaminant proteins (Kcont1 and 2) present in the WSPF, and IgY 
purity and recovery yield using three new mixture compositions of the ABS at pH 6.0. 
System composition 
(PEG 1000 wt % / 
Salt Buffer wt %) 
Purity ± σ (%) Yield ± σ (%) Kcont1 ± σ Kcont2 ± σ 
18 / 15 41.07 ± 0.46 79.80 ± 3.09 2.04± 0.04 1.65 ± 0.12 
18 / 13 39.31 ± 0.97 103.83 ± 2.36 3.90 ± 0.05 1.80 ± 0.39 
21 / 16 27.19 ± 0.09 53.81 ± 0.56 n.d.* 8.81 ± 2.67 
21 / 14 22.81 ± 2.02 35.94 ± 3.30 n.d.* n.d.* 
 * n.d.: non-determined 
 
 Comparing the three new mixture compositions with the initially studied ABS, a new mixture 
reveals a top contender to be used in further FCPC trials, with some advantages. In terms of purity, 
no mixture surpassed the first studied system, with only the 18 wt % PEG 1000 + 13 wt % phosphate 
salt buffer system achieving comparable results (39.31 ± 0.97% versus 41.07 ± 0.46%). The loss of 
some purification capacity on the first step, using only the ABS as a purification tool, is an adequate 
trade-off considering that the goal is the application of the ABS in FCPC. When it comes to yield, the 
18 wt % PEG 1000 + 13 wt % phosphate salt buffer system clearly performs better. The yield value 
of the mentioned system is 103.83 ± 2.36 %, showing not only that this system is partitioning IgY 
exclusively to its top phase, as thoroughly justified in section 3.3.1 and Figure 9, but that there is also 
no loss of IgY. In comparison, the first studied system leads to an yield of 79.80 ± 3.09 %.   
The last parameter that demonstrates the 18 wt % PEG 1000 + 13 wt % phosphate salt buffer 
system as a more suitable candidate for FCPC assays is the partition coefficient of the contaminant 
proteins. The K values relate to the exit time of its compound in a chromatographic assay, due to its 
affinity to the mobile and stationary phases. Therefore, a higher difference between Kcont1 and Kcont2 
will allow an easier separation of the different contaminant proteins in FCPC. In fact, the K values of 
both contaminant proteins, 3.90 ± 0.05 and 1.80 ± 0.39, are more distinct than the ones reported for 
first system studied (2.04± 0.04 and 1.65 ± 0.12). It should be remarked that the remaining systems 
do not present peaks for both groups of contaminant proteins (in the case of the 21 wt % PEG 1000 
+ 14 wt % phosphate salt buffer system) or for one of them (in the case of the 21 wt % PEG 1000 + 
16 wt % phosphate salt buffer system) in the bottom phase. This indicates that the separation of IgY 
from the contaminants is not being achieved, with the partitioning of IgY and contaminants occurring 
to the same phase.  
46 
 
In summary, the 18 wt % PEG 1000 + 13 wt % phosphate salt buffer ABS is the clear choice 
to pursue the FCPC trials, due to the greater distinction between the partition coefficients for the 
contaminants, and high extraction yield and  purity. 
 
3.3.4 Purification of IgY using ABS and ultrafiltration 
Ultrafiltration was investigated as a subsequent  method of ABS to improve the purification 
of IgY. Ultrafiltration was applied to the top phase of the ABS also chosen for FCPC assays, identified 
in the previous section, and composed of 18 wt % PEG 1000 + 13 wt % phosphate salt buffer at pH 
6.0. The SE-HPLC chromatograms of the top phase (PEG-rich phase enriched in IgY) of the original 
ABS and after ultrafiltration are presented in Figure 10, along with the chromatogram of the WSPF 
used in the ABS composition. The analysis of the results obtained reveals that an ultrafiltration step 
after the IgY extraction  improves the IgY purity (in 8 %, from  39 % to 47 %). 
 
 
Figure 10- SE-HPLC spectra of the top phase of the 18 wt % PEG 1000 + 13 wt % phosphate 
buffer at pH 6.0: top-phase of the ABS (blue), top phase of the same ABS after six ultrafiltration cycles 
(green), and WSPF used in ABS formation (orange). 
 
The fractions collected from each ultrafiltration cycle were also analyzed in SE-HPLC, in 
order to verify the possible effectiveness of extra ultrafiltration cycles. The chromatograms obtained 
are shown in Appendix D (Figures D 1 – 5), and a summary of the percentage of contaminants in 
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each fraction is given in Figure 11. The results from fraction 3 are not presented due to an anomaly 
found in the chromatogram, assumed to be due to a mechanical error in the SE-HPLC apparatus. 
From the gathered data, it is apparent that the first and last filtration steps are the most effective in 
removing impurities from the sample, with the first being composed of about 74 % impurities, and 
fraction 6 presenting about 75 % of contaminants. While the initial cycle is effective in removing 
contaminants, the trend for the subsequent cycles shows an increase in impurity percentage, revealing 
that more cycles can be incorporated on the ultrafiltration assay until a plateau is reached.  
 
 
Figure 11 – Contaminant proteins percentage in the fractions obtained by ultrafiltration, 
calculated from the SE-HPLC spectra. F1-6 represent the fraction collected after each of the six 
ultrafiltration cycles performed. 
 
Although it was not observed a significant improvement on the IgY purity after ultrafiltration, 
it should be highlighted that this approach allows the removal of PEG 1000. Most applications of 
IgY, clinical or laboratory ones, require it to be not only pure but also solubilized in a salt solution, 
while other applications, such as using IgY as a food additive, do not benefit from polymer removal. 
The chromatograms presented in Appendix D (Figures D 1-5) were additionally analyzed to infer the 
polymer presence, concluding that all of the PEG 1000 is removed after the forth ultrafiltration cycle.  
Figure 12 shows the chromatograms of fraction 4 and the top phase of the ABS, used for 
ultrafiltration. 
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Figure 12 – SE-HPLC spectra of the top phase of the 18 wt % PEG 1000 + 13 wt % phosphate salt 
buffer at  pH 6.0: ABS (orange) and the fraction obtained after the 4th ultrafiltration cycle (blue), with 
the peaks pertaining to PEG 1000 outlined. 
 
The last important parameter to investigate in the performance of ultrafiltration for the 
purification of IgY is the loss of the target protein. In this sense, the mass of IgY present in the 
concentrated sample, after all the filtration cycles, and on the original top phase of the ABS used was 
calculated. Ultrafiltration leads to a loss of ca. 36 % of IgY, with the top phase of the ABS containing 
73.2 µg, compared to the 46.7 µg found in the concentrated sample. This results reinforces a potential 
negative point, in concern to the overall yield of the process, and that might be exacerbated with more 
cycles. 
The use of ultrafiltration leads to an increase in the IgY purity, when compared to the single-
step extraction by ABS, while also providing a complete removal of the polymer. An important 
negative aspect, is however the loss of IgY. Ultrafiltration might thus be useful for laboratory 
purification assays due to its simplicity and overall low cost.  
 
3.3.5 Purification of IgY in FCPC using ABS  
With the previous screening on the ABS ability to purify IgY, and after confirming their 
feasibility for use in FCPC, ABS were finally tested for their capacity to extract and purify IgY in 
FCPC. While the 18 wt % of PEG 1000 + 13 wt % of phosphate salt buffer at pH 6.0 was considered 
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optimal, additional tests were carried out using the 18 wt % of PEG 1000 + 15 wt % of phosphate salt 
buffer ABS at pH 6.0.  
Since the validation of the system, described in section 3.1, was carried out using an ABS 
composed of 12.5 wt % of PEG 1000 + 12.5 wt % of phosphate salt, it is imperative to confirm that 
the behavior is the same for the ABS constituted by 18 wt % of PEG 1000 + 15 wt % of phosphate 
salt buffer, when it comes to the stationary phase retention. A process similar to the one detailed in 
section 3.1. was carried out, mainly regarding the determination of the Sf value for the FCPC assay 
with this system composition. The ascending mode of operation was chosen since IgY was found to 
partition exclusively to the top phase, rich in PEG 1000. Therefore, it would be the first protein to be 
collected in the chromatographic assay. With 2000 rpm of rotation speed and 2.0 mL min-1 of flow 
rate, an Sf of 39.0 % was achieved, a lower value than the Sf values obtained in section 3.1, but well 
above the 20 % established minimum.  
The first purification trial was performed with the injection of 5 g of both phases of an ABS 
composed of 18 wt % of PEG 1000 + 15 wt % of phosphate salt buffer at pH 6.0 + 67.0 wt % WSPF, 
using the following operational conditions: ascending mode, 2000 rpm at a 2.0 mL min-1 flow rate. 
In this trial, no IgY was detected in any collected fraction, and during the procedure a loss of some 
stationary phase inside the column was detected. A follow-up run was performed, this time injecting 
only the top phase of a 10 g ABS composed of 18 wt % PEG 1000 + 15 wt % of phosphate salt buffer 
at pH 6.0 + 67 wt % WSPF, reducing the flow rate to 1.5 mL min-1 and maintaining the rotation at 
2000 rpm, in the ascending mode. Also with this system and conditions, IgY was not identified in the 
collected fractions. Furthermore, a severe pressure drop and loss of stationary phase in the column in 
a short period was observed, indicating an inefficient stationary phase retention. A different approach 
was then considered, using the same conditions, but instead of injecting the top phase of a PEG 1000 
+ phosphate salt buffer at pH 6.0 + WSPF, the same system was prepared with water instead of the 
WSPF. The top phase of the PEG 1000 + phosphate salt buffer at pH 6.0 + H2O was then mixed with 
WSPF and injected, resulting in a stationary phase retention of 48.5 %. Despite the adequate Sf value 
obtained, IgY was not identified in the collected fractions. 
In the previous trials, IgY was not identified, evidencing that the protein is being lost. 
Therefore, in an attempt to solve this problem, a different ABS was tested, namely the 18 wt % PEG 
1000 + 13 wt % of phosphate salt buffer at pH 6.0 + 69 wt % WSPF ABS. The second set of FCPC 
assays were validated for its capacity to extract IgY from the WSPF in section 3.3.2. While this 
system led a lower IgY purity level, it was considered as more adequate for use in FCPC do to a 
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higher difference in the contaminant’s partition coefficient. Similarly to the previous purification 
assays, the Sf  value was calculated and taken into account. 
Considering the loss of protein that occurred in previous FCPC assays, most likely due to 
denaturation, it was decided that the sample injected into the FCPC loop should not be the result of a 
one-step ABS extraction, as done previously with the phases from the PEG 1000 + phosphate salt 
buffer at pH 6.0 + WSPF. To lower the denaturation effect resulting from the one-step ABS 
extraction, the sample injected in the following assays was composed of 8g of WSPF + 2g of the top 
phase of a 18 wt % of PEG 1000 + 13 wt % of phosphate salt buffered at pH 6.0 ABS + 69% H2O. 
An increase in the flow-rate was also deemed necessary, postulating that the contact time between 
the IgY and the phases was causing this issue. In that sense, the first assay was done in the ascending 
mode of operation, using a 2.5 mL/min flow-rate, also increasing the rotation to 2500 rpm, in an 
attempt to offset a possible hit to phase retention as a result of the increased flow-rate. While this 
assay presented a remarkably low Sf value, 16.7%, lower than the 20% required, some IgY 
purification was indeed achieved, as demonstrated in the chromatogram presented in Figure 13. As 
the purity of the end sample was only about 29.5%, possibly due to low retention of the stationary 
phase, further optimizations were performed.  
 
 
Figure 13 - SE-HPLC spectra of fraction 9 collected from the FCPC assay using the 18 wt % PEG 
1000 + 13 wt % phosphate buffer at pH 6.0 ABS, performed with 2.5 mL/min flow rate and 2500 rpm 
in the ascending mode. 
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As an increase in the rotation speed does not lead to a sufficient Sf value, an additional assay 
was performed in the ascending mode using 2000 rpm and a 3.0 mL/min flow rate. The chromatogram 
of the seventh fraction collected from this assay is presented in Figure 14. This assay leads to more 
promising results, not only presenting a higher Sf than the previous one, but also a higher IgY purity  
(50.6 %). This purity effectiveness surpassed both the extraction assays using only the ABS and the 
combination of ABS extraction and ultrafiltration, disclosing the higher potential of  FCPC for the 
purification of biopharmaceuticals.  
 
 
Figure 14 - SE-HPLC spectra of fraction 7 collected from the FCPC assay using the 18 wt % PEG 
1000 + 13 wt % phosphate buffer at 6.0 pH ABS, performed with 3.0 mL/min flow rate and 2000 rpm 
in the ascending mode. 
  
Overall, the first FCPC assays were performed using the 18 wt % of PEG 1000 + 15 wt % of 
phosphate salt buffer at pH 6.0 + 67 wt % WSPF, using the ascending mode of FCPC operation, at 
2000 rpm. A flow rate of 2.0 mL/min was tested first and then lowered to 1.5 mL/min. The samples 
injected in the FCPC loop were the phases obtained after a single-step IgY extraction, using the ABS 
referred above. These first assays revealed a complete loss of IgY. As such, the following assays 
attempted to thwart the IgY loss by injecting a mixture of 8 g of WSPF + the top phase of a 18 wt % 
of PEG 1000 + 13 wt % of phosphate salt buffer at pH 6.0  + 69 wt % H2O. This system was deemed 
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time IgY is present inside the FCPC apparatus and, as such, to decrease its loss. These optimization 
steps allowed to obtain IgY with a purity level of 51%. 
 
3.4 Secondary structure and stability of IgY 
Circular Dichroism (CD) can be defined as the unequal absorption of left-handed and right-
handed circularly polarized light, in which the differential absorption effect of light by asymmetric 
molecules can be appraised 179. CD is appropriate for determining the secondary structure of proteins 
due to the amides present in the polypeptide backbone, that are characteristic of proteins, and which 
have a chromophoric activity that effectively shifts or splits light into multiple transitions due to 
exciton interactions between electrons 180. Because protein CD spectra are dependent on their 
conformation, this technique can be used to monitor and evaluate conformational changes due to 
binding interactions 179. 
The evaluation of the IgY stability was carried out by the analysis of CD spectra, in 
comparison to a solution of pure IgY commercially acquired. This analysis was carried out according 
to the representative CD spectra of proteins shown by Greenfield 179, presented in Figure 15. A typical 
CD spectra of proteins rich in α-helixes show a negative band at 222 and 208 nm, while proteins 
composed mainly of β-sheets can be identified by a negative band at 218 nm. Disordered or otherwise 
very unstable proteins can be identified by relatively low, but not negative, CD values above 210 nm 
179.  
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Figure 15 - Representative CD spectra for proteins, adapted from Greenfield 179. 1: α-helix; 2: β-sheet; 
3: disordered proteins. 
 
The results for the IgY samples obtained according to the protocols described in section 
2.3.2.1, will be shown separately in the following figures, with the IgY standard 8commercially 
acquired sample) shown in all of them for comparison. Figure 16 shows the CD results for the IgY in 
PEG 1000 solutions, at 10, 20 and 30 wt %. IgY in the 10 and 20 wt% of PEG 1000 solutions does 
not present a significant loss of secondary structure, as shown by their spectra resemblance with the 
IgY standard, with a negative band at 218 nm characteristic of proteins mainly comprising β-sheets 
37,69. However, for 30 wt% of PEG 1000, IgY displays a highly significant loss of its secondary 
structure, as shown by the spectras lack of a smoothly defined curve, and by presenting a less 
noticeable negative band at 218 nm. Another indication of the negative effect of the high 
concentration of PEG 1000 towards IgY is the signal intensity. A loss of the CD signal intensity 
indicates two phenomena: a loss of protein, due to precipitation, making these unable to be detected 
by CD; and an increased contribution of the positive band above 210 nm, characteristic of disordered 
proteins. This result is however expected, considering the strong capacity of polymers like PEG to 
precipitate proteins, more significant at higher concentrations 178. 
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Figure 16 - CD spectra of the IgY standard in PBS at 1.5 mg/mL (yellow), IgY + PEG 1000 at 10 wt % 
(blue),  IgY + PEG 1000 at 20 wt % (orange), and IgY + PEG 1000 at 30 wt % (gray). 
 
Figure 17 presents the CD spectra for the IgY + phosphate salt solutions at 5.5, 6.0, 6.5, 7.5 
and 8.0 pH values. Almost all of the samples composed of salt buffer + IgY revealed similar CD 
spectra, although with a rougher pattern than that observed in the IgY standard, but still presenting a 
noticeable negative band at the 218 nm. The sample at pH 8.0 shows the most distinct spectral profile, 
with a shift of its negative band from the expected 218 nm to 222 nm, indicating a significant loss of 
the protein structure. A reduction in the signal intensity is also noticeable in these spectra, with a 
more pronounced effect for samples prepared at higher pH values. These results show that the strong 
salting-out effect caused by the ions K2+ and HPO4
- 176, when present in higher concentrations at 
alkaline medium, is relevant to induce the protein loss of stability. 
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Figure 17 - CD spectra of the IgY standard in PBS at 1.5 mg/mL (yellow) and the IgY + phosphate salt 
buffers at 5.5 (blue), 6.0 (green), 6.5 (orange), 7.5 (brown) and 8.0 (gray) pH values. 
 
Figure 18 shows the CD spectra for the top phase of the two ABS analyzed: 18 wt % of PEG 
1000 + 15 wt % phosphate buffer at pH 6.0 + 67 wt % of the IgY aqueous solution (ABS 18/15/67) 
and 18 wt % of PEG 1000 + 13 wt % phosphate buffer at pH 6.0 + 69 wt % of the IgY aqueous 
solution (ABS 18/13/69). While both samples show similar spectra, they differ however in the signal 
intensity, indicative of loss of the protein secondary structure. The ABS 18/15/67 spectrum has a 
remarkably lower signal intensity when compared to both the IgY standard and ABS 18/13/69, 
indicating a more significant loss of secondary structure. The spectrum of the ABS 18/13/69 differs 
from the IgY standard, mainly in a shift from the typical depression at 218 nm band (characteristic of 
β-sheets) to 222 nm (characteristic of α-helix). While this fact could indicate a possible loss of 
secondary structure, it is important to acknowledge that, since the other parameters are highly 
comparable to the IgY standard, other factors could be at play, requiring deeper analyses. Considering 
that the shift occurs to bands characteristic of the α-helix secondary structure, it is possible that this 
sample may be contaminated with other proteins. 
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Figure 18- CD spectra of the IgY standard in PBS at 1.5 mg/mL (yellow), the IgY + TP of the 18 wt % 
PEG 1000 + 15 wt % phosphate-based salt buffers at 6.0 ph (blue) and the IgY + TP of the 18 wt % 
PEG 1000 + 13 wt % phosphate-based salt buffers at 6.0 ph (green). 
 
Additionally to the CD analysis, stability and activity studies were carried out with ELISA for 
the IgY obtained from the 3 purification approaches presented in this work: one-step purification 
method with the 18 wt % of PEG 1000 + 13 wt % phosphate buffer at pH 6.0 + 69 wt % WSPF ABS; 
two-step purification method with ABS and ultrafiltration; and multiple-step purification approach 
using the same ABS in FCPC. Since these techniques result in samples with similar purity, it is 
expected that the concentration of active IgY determined by ELISA will change primarily due to the 
effect of each of these techniques on the IgY activity, and as such, IgY stability. The IgY 
concentration results are presented in Figure 19. The analysis of these results reveals a much higher 
concentration of biologically active IgY for the process using ultrafiltration, with 553.77 ng/mL, 
against the ABS extraction and the FCPC results, with 50.07 and 29.19 ng/mL of IgY, respectively. 
The ELISA results for active IgY after the ABS extraction followed by ultrafiltration should not be 
higher than the result for the IgY purified using just the one-step ABS extraction. This discrepancy 
can be attributed to the blocking effect of PEG 1000 in ELISA assays 181, and therefore, after the 
ultrafiltration step, the polymer has been removed and the antibody concentration/activity increases. 
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Figure 19 – Concentration of IgY determined by ELISA for the top phase of the 18 wt % of PEG 1000 
+ 13 wt % phosphate buffer at pH 6.0 + 69 wt % WSPF ABS (green), after ultrafiltration (blue), and 
after FCPC purification (orange). 
 
In summary, the stability assays using CD allowed the evaluation of the effect of the ABS 
phase-forming components on the IgY stability. The most important set of data is the for IgY stability 
in PEG 1000 solutions at 30 wt%, mainly because the top phase of the studied ABS is composed of 
ca. 30 wt% of PEG, as determined using the systems TLLs and binodal data. The CD spectra reveal 
that at this PEG concentration there is significant loss of the target protein secondary structure, a 
result that coincides with the analysis done on the FCPC assays and loss of protein. The results for 
the CD spectra of IgY + phosphate buffer at different pH values are less important, particularly 
considering that the IgY partitions almost exclusively to the PEG-rich phase. Yet, they provide 
relevant information on the effect of the pH in the IgY secondary structure, which could be a limiting 
factor if a high pH buffer solution is used. While the ELISA assays did not permit a direct comparison 
of the several purification methodologies, it revealed an important blocking effect exerted by the 
polymer that should be taken into account when considering the aimed application of IgY.  
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4.1 Conclusions and future work 
This work aimed to introduce aqueous biphasic systems and the FCPC technology as a 
purification platform for IgY from egg yolk. A literature review was firstly carried out in order to 
find a starting point for a system that should have two essential characteristics: being able to 
effectively separate IgY from the contaminant proteins of egg yolk and be feasible to be used in 
FCPC. This research work showed that a PEG 1000 + K2HPO4 ABS has the potential for such an 
approach, and as such, the first step consisted on the validation of the system viability in FCPC. The 
system capacity to be retained inside the FCPC column was tested through the calculation of the 
stationary phase retention. 
After the validation of the system applicability in FCPC, the next step comprised the 
description of these systems phase diagrams, by including the analysis of the effect of the pH in their 
capacity to form two phases, i.e. ABS. This step revealed that higher pH values are more favorable 
for the separation into two phases. With the binodal curves presented, for which a good correlation 
was achieved, the respective tie-lines were determined, allowing to conclude on the composition of 
each phase in equilibrium for the mixtures for which the partition studies were performed. 
After the determination of the ABS phase diagrams, the mixture formed by18 wt % of PEG 
1000 and 15 wt % of phosphate salt buffer was chosen, aiming at maximizing the water content of 
the system while still guaranteeing that it presents a biphasic behavior. In the extraction studies of 
IgY, some protein precipitation was evident at the interphase, more pronounced in ABS of higher pH 
values . By the analysis of both phases by SE-HPLC it was revealed that all the proteins in the WSPF 
have a higher affinity to the top-rich phase (polymer-rich phase), in which high yields were found, 
yet with low IgY purity levels (≈ 30-40 %). SE-HPLC also revealed that the system is quite specific 
for IgY, which partitions completely to the top phase, while the contaminants partition among both 
phases, being thus promising to be applied in FCPC. Further optimization of the system compositions 
was attempted, demonstrating that an ABS consituted by 18 wt % of PEG 1000 + 13 wt % phosphate 
salt buffer is more favorable for FCPC purification due to the IgY higher yield obtained. 
The purification of Igy using FCPC was best achieved for ABS formed by 18 wt % PEG 1000 
+ 13 wt % phosphate salt buffer at pH 6.0, using the ascending mode, a 3.0 mL/min flow-rate and 
2000 rpm of rotation speed. An adequate system retention was guaranteed by a high Sf value for the 
same system, and IgY with ≈ 51 % purity was obtained. An alternative purification method based on 
ultrafiltration using the same ABS was also attempted, achieving a lower purity, 47 %, but enabling 
the removal of the polymer which might be useful depending on the intended use of IgY.  
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The stability of the target protein was to be assessed by circular dichroism, concluding that 
the protein did not show significant signs of degradation of its secondary structure, rich in β-sheets, 
in PEG 1000 aqueous solutions of low concentration (up to 20 wt%). In phosphate salt buffer 
solutions some loss of stability of IgY was found, particularly for higher pH values. The ELISA 
assays revealed an important blocking effect for IgY, as detailed by the much higher concentration 
of active IgY after the ultrafiltration assays, while also demonstrating that FCPC purification further 
promotes the loss of biological activity, when compared to the single-step extraction using just the 
ABS. 
Overall, the methods investigated in this work for IgY purification have some advantages and 
disadvantages. While FCPC is the best method in terms of possible industrial application, due to the 
scale-up possibilities and IgY purity obtained, it is more disruptive towards the protein stability than 
just the single-step extraction using ABS. The ultrafiltration and one-step ABS methodologies also 
lead to high purity levels of IgY, albeit more limited in terms of scale-up, and being more suitable for 
laboratory purifications.   
As future work, and based on the work developed, other operational conditions for the FCPC 
should be tested, particularly in the finding of other phase-forming components and compositions 
which could allow the complete purification of IgY, and using higher flow-rates to turn the process 
faster and more profitable. The two-step purification method with ABS and ultrafiltration should also 
be refined by applying more filtration cycles in an attempt to increase the end product purity, while 
still considering the final mass of IgY obtained, that can be reduced with more cycles. Further 
evidence of the blocking effect of PEG 1000 should be obtained by ELISA analysis of IgY purified 
by FCPC, yet after the polymer removal. 
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Appendix A: Calibration curve for the IgY 
quantification by SE-HPLC  
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Figure A 1- Calibration curve (absorbance vs concentration of IgY) by SE-HPLC. 
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Appendix B: Experimental binodal data for 
the PEG + phosphate-based salts + H2O 
Ternary Systems  
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Table B 1 - Experimental weight fraction data for the systems composed of PEG 1000 (1) + phosphate-
based salt (2) + H2O, at pH 5.5 and 6.0, at 298 K and atmospheric pressure. 
pH 5.5 pH 6.0 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
55.680 1.680 46.812 2.212 21.179 9.317 9.426 16.776 
50.288 2.242 41.979 2.449 20.788 9.563 8.871 17.173 
47.080 2.753 40.286 2.822 20.490 9.674 8.514 17.483 
42.901 3.168 38.434 3.124 20.056 9.945 7.996 17.863 
40.423 3.555 37.504 3.435 19.773 10.067 7.415 18.283 
38.153 3.935 36.075 3.838 19.500 10.169 6.975 18.601 
36.336 4.208 34.835 4.109 19.016 10.343 6.283 19.076 
35.138 4.501 33.556 4.405 18.681 10.565 6.045 19.404 
34.018 4.812 32.424 4.726 18.360 10.753 5.329 19.913 
32.755 5.208 31.378 4.970 18.063 10.939 5.014 20.256 
31.697 5.434 30.677 5.297 17.864 11.021 4.328 20.936 
30.774 5.690 29.800 5.478 17.573 11.233 3.957 21.315 
29.352 6.288 29.271 5.705 17.281 11.414 3.508 21.731 
27.906 6.999 28.711 5.932 16.791 11.901 3.082 22.120 
27.232 7.190 28.190 6.174 16.002 12.397 2.674 22.776 
26.201 7.572 27.428 6.336 15.631 12.720 2.228 23.273 
25.285 7.975 26.449 6.757 15.164 12.951 1.839 24.279 
24.342 8.343 25.950 6.955 14.715 13.283 1.456 25.634 
23.256 8.905 25.523 7.138 14.481 13.496   
22.195 9.422 25.041 7.340 14.007 13.754   
21.130 10.025 24.625 7.520 13.701 13.941   
20.372 10.386 23.816 8.152 12.941 14.426   
19.195 11.075 23.442 8.313 12.582 14.671   
18.137 12.201 23.051 8.478 12.127 15.004   
16.921 12.948 22.699 8.598 11.781 15.201   
14.017 15.082 22.333 8.757 11.035 15.714   
12.605 16.047 21.848 9.072 10.824 15.871   
10.459 17.516 21.523 9.195 10.041 16.368   
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Table B 2 - Experimental weight fraction data for the systems composed of PEG 1000 (1) + phosphate-
based salt (2) + H2O, at pH 6.5 and 7.5, at 298 K and atmospheric pressure. 
6.5 pH 7.5 pH 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
57.131 1.584 15.084 12.119 56.144 2.013 20.881 7.982 3.445 18.579 
50.928 2.163 14.654 12.359 47.468 2.106 20.412 8.173 2.971 19.105 
45.557 2.843 14.236 12.624 44.638 2.318 20.089 8.343 2.442 19.674 
40.648 3.241 13.853 12.897 42.737 2.625 19.547 8.562 2.037 21.039 
37.545 3.936 13.429 13.196 40.715 3.246 19.247 8.751   
34.461 4.486 12.970 13.510 37.780 3.349 18.907 8.932   
32.452 4.982 12.481 13.828 36.045 3.755 18.563 9.112   
30.585 5.396 12.004 14.150 34.303 3.870 18.141 9.322   
29.432 5.923 11.444 14.497 33.628 4.088 17.734 9.535   
27.905 6.292 10.879 14.882 32.658 4.232 17.337 9.742   
26.545 6.630 10.273 15.292 32.015 4.438 16.937 9.964   
25.703 7.023 9.669 15.689 31.438 4.644 16.491 10.202   
24.884 7.393 9.285 15.997 30.560 4.792 15.949 10.471   
23.865 7.552 8.571 16.408 29.646 5.309 15.499 10.711   
23.148 7.877 7.829 16.857 28.828 5.419 15.160 10.941   
22.451 8.205 7.452 17.223 28.017 5.633 14.619 11.220   
21.796 8.481 6.663 17.765 27.576 5.802 14.029 11.533   
21.180 8.807 6.257 18.126 27.122 5.950 13.377 11.849   
20.594 9.089 5.904 18.480 26.639 6.155 13.006 12.121   
20.000 9.230 4.948 19.089 26.193 6.290 12.571 12.414   
19.986 9.396 4.487 19.502 25.761 6.413 11.780 12.830   
19.630 9.430 4.027 19.935 25.364 6.544 11.001 13.246   
19.207 9.645 3.581 20.678 24.979 6.648 10.468 13.598   
18.954 9.794 3.126 21.117 24.613 6.755 9.845 13.955   
18.545 10.012 2.594 21.941 24.291 6.861 9.232 14.325   
18.291 10.196 2.008 23.265 23.888 6.969 8.283 14.861   
18.010 10.377 1.518 25.184 23.403 7.250 7.535 15.290   
17.492 10.639 0.867 33.334 23.091 7.356 6.771 15.779   
17.074 10.896   22.769 7.466 6.047 16.258   
16.769 11.111   22.460 7.560 5.648 16.665   
16.382 11.326   22.179 7.648 4.844 17.146   
15.825 11.629   21.880 7.738 4.357 17.618   
15.470 11.867   21.173 7.821 3.919 18.104   
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Table B 3 - Experimental weight fraction data for the systems composed of PEG 1000 (1) + phosphate-
based salt (2) + H2O, at pH 8.0 and with no buffer, at 298 K and atmospheric pressure. 
8.0 pH No Buffer 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
56.884 1.647 15.719 10.274 56.951 1.247 12.853 11.351 
48.417 2.204 15.499 10.344 48.221 2.090 12.698 11.435 
43.182 2.603 15.185 10.524 42.723 2.811 12.540 11.535 
39.835 3.030 14.978 10.585 38.314 3.265 12.333 11.553 
37.723 3.442 14.671 10.778 34.971 3.741   
35.357 3.815 14.479 10.816 31.268 4.742   
33.293 4.046 14.204 11.012 29.104 5.043   
32.349 4.402 13.788 11.406 28.296 5.503   
31.374 4.757 13.526 11.579 26.821 5.822   
30.216 4.917 13.370 11.626 24.687 6.360   
29.434 5.204 13.147 11.759 23.895 6.652   
28.705 5.474 12.917 11.888 23.055 6.877   
27.684 5.647 12.754 11.940 22.547 7.202   
26.991 5.907 12.614 11.998 21.847 7.383   
26.315 6.108 12.383 12.165 21.183 7.569   
25.713 6.330 12.252 12.201 20.759 7.836   
24.907 6.412 12.064 12.321 20.185 8.041   
24.373 6.545 11.596 12.880 19.648 8.182   
23.919 6.725 11.471 12.898 19.266 8.469   
23.464 6.901 11.288 13.024 18.758 8.612   
22.968 7.079 11.171 13.064 18.474 8.727   
22.565 7.229 10.998 13.180 18.194 8.841   
22.149 7.423 10.872 13.204 17.886 9.059   
21.745 7.588 10.713 13.301 17.443 9.162   
21.369 7.744 10.700 13.412 17.049 9.259   
21.026 7.899 10.374 13.613 16.804 9.433   
20.652 8.036 9.498 13.968 16.547 9.577   
20.347 8.125 9.051 14.206 16.315 9.684   
20.004 8.265 8.704 14.550 16.068 9.830   
19.691 8.411 8.267 14.800 15.703 9.898   
19.412 8.511 7.781 15.076 15.489 10.028   
19.106 8.653 7.322 15.392 15.273 10.145   
18.642 8.936 6.808 15.681 15.059 10.288   
18.361 9.029 6.333 16.000 14.744 10.340   
18.084 9.107 5.793 16.325 14.546 10.458   
17.816 9.193 5.395 16.768 14.366 10.596   
17.419 9.464 4.792 17.194 14.032 10.775   
17.152 9.546 4.279 17.554 13.763 10.870   
16.900 9.655 3.380 18.289 13.590 11.005   
16.572 9.870 2.772 18.826 13.353 11.088   
16.322 9.963 2.123 19.803 13.192 11.187   
16.051 10.080   13.015 11.266   
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Appendix C: Phase Diagrams and TLs for 
PEG 1000 + phosphate-based salts + H2O 
ternary systems 
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Figure C 1 - Phase diagram of the ABS composed of PEG 1000 + Phosphate buffer salt at pH 5.5 + 
H2O: tie-line data (●); adjusted binodal data obtained through equation 1 (−); experimental binodal 
curve data (■). 
 
 
Figure C 2 Phase diagram of the ABS composed of PEG 1000 + Phosphate buffer salt at pH 6.5  + 
H2O: tie-line data (●); adjusted binodal data obtained through equation 1 (−); experimental binodal 
curve data (■). 
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Figure C 3 - Phase diagram of the ABS composed of PEG 1000 + Phosphate buffer salts at pH 7.5 + 
H2O: tie-line data (●); adjusted binodal data obtained through equation 1 (−); experimental binodal 
curve data (■). 
 
 
Figure C 4 - Phase diagram of the ABS composed of PEG 1000 + Phosphate buffer salts at pH 8.0 + 
H2O: tie-line data (●); adjusted binodal data obtained through equation 1 (−); experimental binodal 
curve data (■). 
 
0
10
20
30
40
50
60
70
0 5 10 15 20 25 30 35 40 45
[P
E
G
 1
0
0
0
] 
/ 
w
t 
%
[phosphate-based salt] / wt %
0
10
20
30
40
50
60
70
0 5 10 15 20 25 30 35
[P
E
G
 1
0
0
0
] 
/ 
w
t 
%
[phosphate-based salt] / wt %
85 
 
 
 
Figure C 5 - Phase diagram of the ABS composed of PEG 1000 + K2HPO4 salt without pH buffering + 
H2O: tie-line data (●); adjusted binodal data obtained through equation 1 (−); experimental binodal 
curve data (■). 
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Appendix D: SE-HPLC chromatograms for 
the collected fractions of each ultrafiltration 
cycle 
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Figure D 1 - SE-HPLC chromatogram of fraction 1 from the ultrafiltration assay. 
 
 
Figure D 2 - SE-HPLC chromatogram of fraction 2 from the ultrafiltration assay. 
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Figure D 3 - SE-HPLC chromatogram of fraction 4 from the ultrafiltration assay. 
 
 
 
Figure D 4 - SE-HPLC chromatogram of fraction 5 from the ultrafiltration assay. 
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Figure D 5 - SE-HPLC chromatogram of fraction 6 from the ultrafiltration assay. 
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Appendix E: Calibration curve for ELISA 
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Figure E 1- Calibration curve (absorbance vs concentration of IgY) by UV-spectroscopy. 
y = 0,3749ln(x) - 0,5554
R² = 0,9894
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